DK2000149T3 - Kimærisk anti-CD20-antistof - Google Patents

Kimærisk anti-CD20-antistof

Info

Publication number: DK2000149T3
Authority: DK; Denmark
Prior art keywords: antibody; chimeric anti; medicament; administered; substantial
Prior art date: 1992-11-13

Application number

DK08013898T

Other languages

Danish (da)

English (en)

Inventor

Darrell R Anderson

John E Leonard

William H Rastetter

Roland A Newman

Nabil Hanna

Mitchell E Reff

Original Assignee

Biogen Idec Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1992-11-13

Filing date

1993-11-12

Publication date

2009-08-03

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25526490&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK2000149(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1993-11-12 Application filed by Biogen Idec Inc filed Critical Biogen Idec Inc

2009-08-03 Application granted granted Critical

2009-08-03 Publication of DK2000149T3 publication Critical patent/DK2000149T3/da

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S424/00—Drug, bio-affecting and body treating compositions
- Y10S424/80—Antibody or fragment thereof whose amino acid sequence is disclosed in whole or in part
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S424/00—Drug, bio-affecting and body treating compositions
- Y10S424/801—Drug, bio-affecting and body treating compositions involving antibody or fragment thereof produced by recombinant dna technology
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/867—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving immunoglobulin or antibody produced via recombinant dna technology

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Immunology (AREA)
Medicinal Chemistry (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Biochemistry (AREA)
Engineering & Computer Science (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Cell Biology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Oncology (AREA)
Hematology (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Peptides Or Proteins (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)

DK08013898T 1992-11-13 1993-11-12 Kimærisk anti-CD20-antistof DK2000149T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US97889192A	1992-11-13	1992-11-13
US08/149,099 US5736137A (en)	1992-11-13	1993-11-03	Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma

Publications (1)

Publication Number	Publication Date
DK2000149T3 true DK2000149T3 (da)	2009-08-03

Family

ID=25526490

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
DK99123967T DK1005870T3 (da)	1992-11-13	1993-11-12	Terapeutisk anvendelse af kimæriske antistoffer mod humant B-lymfocytdifferentieringsantigen til behandling af B-cellelymfom
DK08013898T DK2000149T3 (da)	1992-11-13	1993-11-12	Kimærisk anti-CD20-antistof

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
DK99123967T DK1005870T3 (da)	1992-11-13	1993-11-12	Terapeutisk anvendelse af kimæriske antistoffer mod humant B-lymfocytdifferentieringsantigen til behandling af B-cellelymfom

Country Status (24)

Country	Link
US (2)	US5736137A (xx)
EP (1)	EP2000149B1 (xx)
KR (1)	KR100365632B1 (xx)
CN (5)	CN1607006B (xx)
AT (2)	ATE421335T1 (xx)
BR (1)	BR1100622A (xx)
CA (1)	CA2626445A1 (xx)
DE (3)	DE69334285D1 (xx)
DK (2)	DK1005870T3 (xx)
ES (2)	ES2326144T3 (xx)
FR (1)	FR04C0018I2 (xx)
GE (3)	GEP20074162B (xx)
HK (3)	HK1109633A1 (xx)
HU (1)	HU219264B (xx)
IL (1)	IL107591A (xx)
LU (1)	LU91620I2 (xx)
MY (1)	MY111196A (xx)
NL (1)	NL300424I1 (xx)
PL (1)	PL175557B1 (xx)
PT (2)	PT2000149E (xx)
SG (1)	SG45294A1 (xx)
TW (1)	TW376320B (xx)
UA (1)	UA27946C2 (xx)
ZA (1)	ZA938466B (xx)

Families Citing this family (729)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4816567A (en)	1983-04-08	1989-03-28	Genentech, Inc.	Recombinant immunoglobin preparations
US5736137A (en) *	1992-11-13	1998-04-07	Idec Pharmaceuticals Corporation	Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
US7744877B2 (en) *	1992-11-13	2010-06-29	Biogen Idec Inc.	Expression and use of anti-CD20 Antibodies
NZ258392A (en) *	1992-11-13	1997-09-22	Idec Pharma Corp	Chimeric and radiolabelled antibodies to the b lymphocyte cellsurface antigen bp35 (cd-20) and their use in the treatment of b cell lymphona
US5595721A (en) *	1993-09-16	1997-01-21	Coulter Pharmaceutical, Inc.	Radioimmunotherapy of lymphoma using anti-CD20
US5885574A (en) *	1994-07-26	1999-03-23	Amgen Inc.	Antibodies which activate an erythropoietin receptor
WO1996004925A1 (en) *	1994-08-12	1996-02-22	Immunomedics, Inc.	Immunoconjugates and humanized antibodies specific for b-cell lymphoma and leukemia cells
US8771694B2 (en) *	1994-08-12	2014-07-08	Immunomedics, Inc.	Immunoconjugates and humanized antibodies specific for B-cell lymphoma and leukemia cells
US20030180290A1 (en) *	1995-06-07	2003-09-25	Idec Pharmaceuticals Corporation	Anti-CD80 antibody having ADCC activity for ADCC mediated killing of B cell lymphoma cells alone or in combination with other therapies
US6373497B1 (en) *	1999-05-14	2002-04-16	Zight Corporation	Time sequential lookup table arrangement for a display
US7033589B1 (en) *	1997-02-20	2006-04-25	Biogen Idec Ma Inc.	γ-1 anti-human CD23 monoclonal antibodies and use thereof as therapeutics
US6893636B2 (en) *	1997-02-20	2005-05-17	Biogen Idec Ma Inc.	Gamma-1 and gamma-3 anti-human CD23 monoclonal antibodies and use thereof as therapeutics
US6991790B1 (en) *	1997-06-13	2006-01-31	Genentech, Inc.	Antibody formulation
US6171586B1 (en) *	1997-06-13	2001-01-09	Genentech, Inc.	Antibody formulation
US20040213789A1 (en) *	1997-09-02	2004-10-28	Oron Yacoby-Zeevi	Heparanase activity neutralizing anti-heparanase monoclonal antibody and other anti-heparanase antibodies
US20020088019A1 (en) *	1997-09-02	2002-07-04	Oron Yacoby-Zeevi	Methods of and pharmaceutical compositions for improving implantation of embryos
US20030161823A1 (en) *	1998-08-31	2003-08-28	Neta Ilan	Therapeutic and cosmetic uses of heparanases
US6177545B1 (en) *	1997-09-02	2001-01-23	Insight Strategy & Marketing Ltd.	Heparanase specific molecular probes and their use in research and medical applications
US6562950B2 (en) *	1997-09-02	2003-05-13	Insight Strategy & Marketing Ltd.	Heparanase activity neutralizing anti-heparanase monoclonal antibody
US20010006630A1 (en) *	1997-09-02	2001-07-05	Oron Yacoby-Zeevi	Introducing a biological material into a patient
US6699672B1 (en)	1997-09-02	2004-03-02	Insight Biopharmaceuticals Ltd.	Heparanase specific molecular probes and their use research and medical applications
US6194551B1 (en)	1998-04-02	2001-02-27	Genentech, Inc.	Polypeptide variants
US6528624B1 (en) *	1998-04-02	2003-03-04	Genentech, Inc.	Polypeptide variants
US6242195B1 (en)	1998-04-02	2001-06-05	Genentech, Inc.	Methods for determining binding of an analyte to a receptor
ES2434961T5 (es) *	1998-04-20	2018-01-18	Roche Glycart Ag	Ingeniería de glicosilación de anticuerpos para mejorar la citotoxicidad celular dependiente del anticuerpo
US6455043B1 (en) *	1998-08-11	2002-09-24	Idec Pharmaceuticals Corporation	Combination therapies for B-cell lymphomas comprising administration of anti-CD20 antibody
US20030217375A1 (en) *	1998-08-31	2003-11-20	Eyal Zcharia	Transgenic animals expressing heparanase and uses thereof
US20010033839A1 (en) *	1999-10-04	2001-10-25	Emilio Barbera-Guillem	Vaccine and immunotherapy for solid nonlymphoid tumor and related immune dysregulation
US6224866B1 (en)	1998-10-07	2001-05-01	Biocrystal Ltd.	Immunotherapy of B cell involvement in progression of solid, nonlymphoid tumors
CN1679934B (zh)	1998-11-09	2012-09-05	生物基因Idec公司	使用抗cd20嵌合抗体治疗循环肿瘤细胞相关的血液恶性肿瘤
JP2002529429A (ja) *	1998-11-09	2002-09-10	アイデック・ファーマシューティカルズ・コーポレイション	Ｂｍｔまたはｐｂｓｃ移植を受ける患者のキメラ化抗ｃｄ２０抗体による治療。
AU1727500A (en) *	1998-11-17	2000-06-05	Tanox, Inc.	Bispecific molecules cross-linking itim and itam for therapy
KR100887482B1 (ko) *	1999-01-15	2009-03-10	제넨테크, 인크.	효과기 기능이 변화된 폴리펩티드 변이체
US6737056B1 (en) *	1999-01-15	2004-05-18	Genentech, Inc.	Polypeptide variants with altered effector function
US7183387B1 (en)	1999-01-15	2007-02-27	Genentech, Inc.	Polypeptide variants with altered effector function
US20020102208A1 (en)	1999-03-01	2002-08-01	Paul Chinn	Radiolabeling kit and binding assay
MY133346A (en) *	1999-03-01	2007-11-30	Biogen Inc	Kit for radiolabeling ligands with yttrium-90
EP1157118A4 (en) *	1999-03-01	2002-07-17	Insight Strategy & Marketing	POLYNUCLEOTID ENCODING A POLYPEPTIDE WITH HEPARANASE ACTIVITY AND ITS EXPRESSION IN GENETICALLY MODIFIED CELLS
MXPA01011279A (es) *	1999-05-07	2002-07-02	Genentech Inc	Tratamiento de enfermedades autoinmunes con antagonistas que se unene a los marcadores de superficie, de celulas b.
EP1645289A1 (en)	1999-05-07	2006-04-12	Genentech, Inc.	Treatment of autoimmune diseases with antagonists which bind to B cell surface markers
AU782160B2 (en) *	1999-06-09	2005-07-07	Immunomedics Inc.	Immunotherapy of autoimmune disorders using antibodies which target B-cells
ITMI991299A1 (it) *	1999-06-11	2000-12-11	Consiglio Nazionale Ricerche	Uso di anticorpi contro antigeni di superficie per il trattamento della malattia trapianto contro ospite
CA2383493C (en) *	1999-06-25	2010-08-10	Genentech, Inc.	Treating prostate cancer with anti-erbb2 antibodies
US7041292B1 (en)	1999-06-25	2006-05-09	Genentech, Inc.	Treating prostate cancer with anti-ErbB2 antibodies
US6949245B1 (en)	1999-06-25	2005-09-27	Genentech, Inc.	Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
US20030086924A1 (en) *	1999-06-25	2003-05-08	Genentech, Inc.	Treatment with anti-ErbB2 antibodies
US20040013667A1 (en) *	1999-06-25	2004-01-22	Genentech, Inc.	Treatment with anti-ErbB2 antibodies
NZ516491A (en) *	1999-07-12	2004-11-26	Idec Pharmaceuticals Inc	Blocking immune response to a foreign antigen using an antagonist which binds to CD20
US8557244B1 (en)	1999-08-11	2013-10-15	Biogen Idec Inc.	Treatment of aggressive non-Hodgkins lymphoma with anti-CD20 antibody
US6451284B1 (en) *	1999-08-11	2002-09-17	Idec Pharmaceuticals Corporation	Clinical parameters for determining hematologic toxicity prior to radioimmunotheraphy
AU6929100A (en) *	1999-08-23	2001-03-19	Biocrystal Limited	Methods and compositions for immunotherapy of b cell involvement in promotion ofa disease condition comprising multiple sclerosis
IL149500A0 (en) *	1999-11-08	2002-11-10	Idec Pharma Corp	Treatment of b cell malignancies using anti-cd40l antibodies in combination with anti-cd20 antibodies and/or chemotherapeutics and radiotherapy
US20020028178A1 (en) *	2000-07-12	2002-03-07	Nabil Hanna	Treatment of B cell malignancies using combination of B cell depleting antibody and immune modulating antibody related applications
AU2048501A (en) *	2000-02-16	2001-08-27	Genentech Inc.	Uses of agonists and antagonists to modulate activity of tnf-related molecules
US20030185796A1 (en) *	2000-03-24	2003-10-02	Chiron Corporation	Methods of therapy for non-hodgkin's lymphoma
CN1441677A (zh) *	2000-03-31	2003-09-10	Idec药物公司	抗细胞因子抗体或拮抗剂与抗－cd20在b细胞淋巴瘤治疗中的联合应用
PT2857516T (pt)	2000-04-11	2017-08-28	Genentech Inc	Anticorpos multivalentes e utilizações dos mesmos
WO2001079299A1 (en)	2000-04-13	2001-10-25	The Rockefeller University	Enhancement of antibody-mediated immune responses
CA2405632A1 (en) *	2000-04-25	2001-11-01	Idec Pharmaceutical Corporation	Intrathecal administration of rituximab for treatment of central nervous system lymphomas
WO2001083781A2 (en) *	2000-04-28	2001-11-08	Millennium Pharmaceuticals, Inc.	14094, a novel human trypsin family member and uses thereof
CN109395082A (zh) *	2000-05-19	2019-03-01	杰南技术公司	用于提高对ErbB拮抗剂癌症治疗的有效应答可能性的基因检测试验
AU2001268363B2 (en)	2000-06-20	2006-08-17	Biogen Idec Inc.	Treatment of B cell associated diseases
EP1292334A4 (en) *	2000-06-22	2003-11-19	Idec Pharma Corp	BISPECIFIC FUSION PROTEIN AND METHOD FOR USE TO ENHANCE THE KILLING OF TARGET CELLS BY EFFECTOR CELLS
US20060034830A1 (en) *	2000-06-28	2006-02-16	Gerngross Tillman U	Immunoglobulins comprising predominantly a GalGlcNAcMan5GLcNAc2 glycoform
US20060034828A1 (en) *	2000-06-28	2006-02-16	Gerngross Tillman U	Immunoglobulins comprising predominantly a GlcNAcMAN5GLCNAC2 glycoform
US20060024304A1 (en) *	2000-06-28	2006-02-02	Gerngross Tillman U	Immunoglobulins comprising predominantly a Man5GlcNAc2 glycoform
US20060029604A1 (en) *	2000-06-28	2006-02-09	Gerngross Tillman U	Immunoglobulins comprising predominantly a GlcNAc2Man3GlcNAc2 glycoform
MXPA03000306A (es) *	2000-07-12	2004-04-05	Idec Pharma Corp	Tratamiento de malignidades de celulas b que usan una combinacion de anticuerpos supresores de celulas b y aplicaciones relacionadas con anticuerpos moduladores inmunes.
MXPA03002262A (es) *	2000-09-18	2003-10-15	Idec Pharma Corp	Terapia de combinacion para tratamiento de enfermedades autoinmunes usando una combinacion de anticuerpos inmunorreguladores/supresores de celulas b.
AU2002213357A1 (en) *	2000-10-20	2002-05-06	Idec Pharmaceuticals Corporation	Variant igg3 rituxan r and therapeutic use thereof
US7507724B2 (en)	2001-01-16	2009-03-24	Sloan-Kettering Institute For Cancer Research	Therapy-enhancing glucan
US7906492B2 (en) *	2001-01-16	2011-03-15	Sloan-Kettering Institute For Cancer Research	Therapy-enhancing glucan
US20030133939A1 (en) *	2001-01-17	2003-07-17	Genecraft, Inc.	Binding domain-immunoglobulin fusion proteins
AU2008200400B2 (en) *	2001-01-17	2012-06-07	Aptevo Research And Development Llc	Binding domain-immunoglobulin fusion proteins
US7829084B2 (en) *	2001-01-17	2010-11-09	Trubion Pharmaceuticals, Inc.	Binding constructs and methods for use thereof
NZ527591A (en) *	2001-01-17	2006-04-28	Trubion Pharmaceuticals Inc	Binding domain-immunoglobulin fusion proteins
US7754208B2 (en) *	2001-01-17	2010-07-13	Trubion Pharmaceuticals, Inc.	Binding domain-immunoglobulin fusion proteins
CA2436180C (en)	2001-01-31	2011-11-08	Idec Pharmaceutical Corporation	Immunoregulatory antibodies and uses thereof
US20070065436A1 (en) *	2001-01-31	2007-03-22	Biogen Idec Inc.	Anti-cd80 antibody having adcc activity for adcc mediated killing of b cell lymphoma cells alone or in combination with other therapies
US20020159996A1 (en)	2001-01-31	2002-10-31	Kandasamy Hariharan	Use of CD23 antagonists for the treatment of neoplastic disorders
PL373835A1 (en)	2001-01-31	2005-09-19	Biogen Idec Inc.	Use of cd23 antagonists for the treatment of neoplastic disorders
US20030211107A1 (en) *	2002-01-31	2003-11-13	Kandasamy Hariharan	Use of CD23 antagonists for the treatment of neoplastic disorders
US20030103971A1 (en) *	2001-11-09	2003-06-05	Kandasamy Hariharan	Immunoregulatory antibodies and uses thereof
ES2364816T3 (es) *	2001-04-02	2011-09-14	Genentech, Inc.	Terapia de combinación.
JP2005500018A (ja) *	2001-04-02	2005-01-06	アイデックファーマスーティカルズコーポレイション	ＧｎＴＩＩＩと同時発現する組換え抗体
JP2004527528A (ja) *	2001-04-09	2004-09-09	プロジェニクス・ファーマスーティカルズ・インコーポレイテッド	抗ｃｄ１９免疫毒素
US20020193569A1 (en) *	2001-06-04	2002-12-19	Idec Pharmaceuticals Corporation	Bispecific fusion protein and method of use for enhancing effector cell killing of target cells
JP2004532642A (ja) *	2001-06-13	2004-10-28	ジェネンテック・インコーポレーテッド	動物細胞の培養方法と動物細胞でのポリペプチド産生
CA2453995A1 (en) *	2001-08-03	2003-02-20	Genentech, Inc.	Tacis and br3 polypeptides and uses thereof
NZ581474A (en) *	2001-08-03	2011-04-29	Glycart Biotechnology Ag	Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity
US7255858B2 (en) *	2001-08-10	2007-08-14	University Of Virginia Patent Foundation	Enhancing the efficacy of immunotherapies by supplementing with complement
US7214428B2 (en) *	2001-09-17	2007-05-08	Invitrogen Corporation	Highly luminescent functionalized semiconductor nanocrystals for biological and physical applications
ATE448077T1 (de) *	2001-09-17	2009-11-15	Life Technologies Corp	Nanokristalle
US7205048B2 (en) *	2001-09-17	2007-04-17	Invitrogen Corporation	Functionalized fluorescent nanocrystal compositions and methods of making
ATE443259T1 (de)	2001-09-20	2009-10-15	Univ Texas	Bestimmung der zirkulierenden therapeutischen antikörper, antigene sowie antigen-antikörper- komplexe mit elisa-tests
CN105131104B (zh)	2001-10-10	2018-11-16	诺和诺德公司	肽的重构和糖缀合
US8323903B2 (en) *	2001-10-12	2012-12-04	Life Technologies Corporation	Antibody complexes and methods for immunolabeling
US20050069962A1 (en)	2001-10-12	2005-03-31	Archer Robert M	Antibody complexes and methods for immunolabeling
CN1329524C (zh) *	2001-10-19	2007-08-01	图尔地区及大学医疗中心	评估抗体治疗反应的方法和组合物
KR100988949B1 (ko) *	2001-10-25	2010-10-20	제넨테크, 인크.	당단백질 조성물
US6671189B2 (en) *	2001-11-09	2003-12-30	Minebea Co., Ltd.	Power converter having primary and secondary side switches
IL161988A0 (en)	2001-11-16	2005-11-20	Corporation Idec Pharmaceutica	Polycistronic expression of antibodies
US20060024292A1 (en) *	2001-12-27	2006-02-02	Gerngross Tillman U	Immunoglobulins comprising predominantly a Gal2GlcNAc2Man3GlcNAc2 glycoform
DE60325334D1 (de)	2002-02-05	2009-01-29	Genentech Inc	Proteinaufreinigung
EP2034009B1 (en)	2002-02-08	2014-01-15	Life Technologies Corporation	Compositions and methods for restoring immune responsiveness in patients with immunological defects basing on cd3/cd28 costimulation
CN101914158A (zh)	2002-02-14	2010-12-15	免疫医疗公司	抗cd 20抗体及其融合蛋白和使用方法
US8287864B2 (en) *	2002-02-14	2012-10-16	Immunomedics, Inc.	Structural variants of antibodies for improved therapeutic characteristics
US20040002587A1 (en) *	2002-02-20	2004-01-01	Watkins Jeffry D.	Fc region variants
US20040132101A1 (en)	2002-09-27	2004-07-08	Xencor	Optimized Fc variants and methods for their generation
US20090042291A1 (en) *	2002-03-01	2009-02-12	Xencor, Inc.	Optimized Fc variants
US20160279239A1 (en)	2011-05-02	2016-09-29	Immunomedics, Inc.	Subcutaneous administration of anti-cd74 antibody for systemic lupus erythematosus and autoimmune disease
US8361464B2 (en)	2002-03-01	2013-01-29	Immunomedics, Inc.	Anthracycline-Antibody Conjugates for Cancer Therapy
AU2003215732B2 (en) *	2002-03-01	2009-12-17	Immunomedics, Inc.	Internalizing anti-CD74 antibodies and methods of use
US8093357B2 (en) *	2002-03-01	2012-01-10	Xencor, Inc.	Optimized Fc variants and methods for their generation
US20030180292A1 (en) *	2002-03-14	2003-09-25	Idec Pharmaceuticals	Treatment of B cell malignancies using anti-CD40L antibodies in combination with anti-CD20 antibodies and/or chemotherapeutics and radiotherapy
WO2003102132A2 (en)	2002-04-26	2003-12-11	Genetech, Inc.	Non-affinity purification of proteins
CN1692127A (zh) *	2002-07-25	2005-11-02	健泰科生物技术公司	Taci抗体及其用途
US8193318B2 (en) *	2002-08-14	2012-06-05	Macrogenics, Inc.	FcγRIIB specific antibodies and methods of use thereof
US8968730B2 (en)	2002-08-14	2015-03-03	Macrogenics Inc.	FcγRIIB specific antibodies and methods of use thereof
US8187593B2 (en) *	2002-08-14	2012-05-29	Macrogenics, Inc.	FcγRIIB specific antibodies and methods of use thereof
US8946387B2 (en) *	2002-08-14	2015-02-03	Macrogenics, Inc.	FcγRIIB specific antibodies and methods of use thereof
US8044180B2 (en) *	2002-08-14	2011-10-25	Macrogenics, Inc.	FcγRIIB specific antibodies and methods of use thereof
DK2364996T3 (en)	2002-09-27	2017-02-06	Xencor Inc	Optimized Fc variants and methods for their formation
MXPA05004022A (es) *	2002-10-17	2005-10-05	Genmab As	Anticuerpos monoclonales humanos contra cd20.
JP4033390B2 (ja) *	2002-10-30	2008-01-16	独立行政法人科学技術振興機構	不死化ナチュラルキラー細胞株
US20040258685A1 (en) *	2002-11-21	2004-12-23	Genentech, Inc.	Therapy of non-malignant diseases or disorders with anti-ErbB2 antibodies
SE0203731D0 (sv) *	2002-12-13	2002-12-13	Mitra Medical Technology Ab	Reagent
SI2289936T1 (sl) *	2002-12-16	2017-10-30	Genentech, Inc.	Imunoglobulinske variante in njihove uporabe
WO2004063351A2 (en) *	2003-01-09	2004-07-29	Macrogenics, Inc.	IDENTIFICATION AND ENGINEERING OF ANTIBODIES WITH VARIANT Fc REGIONS AND METHODS OF USING SAME
US7960512B2 (en)	2003-01-09	2011-06-14	Macrogenics, Inc.	Identification and engineering of antibodies with variant Fc regions and methods of using same
JP4177123B2 (ja) *	2003-01-10	2008-11-05	富士通株式会社	配線図形検証方法、プログラム及び装置
US20040202666A1 (en) *	2003-01-24	2004-10-14	Immunomedics, Inc.	Anti-cancer anthracycline drug-antibody conjugates
MXPA05007940A (es) *	2003-01-27	2007-06-14	Biogen Idec Inc	Composiciones y metodos para el tratamiento del cancer usando igsf9 y liv-1.
US8388955B2 (en) *	2003-03-03	2013-03-05	Xencor, Inc.	Fc variants
US20090010920A1 (en) *	2003-03-03	2009-01-08	Xencor, Inc.	Fc Variants Having Decreased Affinity for FcyRIIb
KR20110044809A (ko)	2003-04-09	2011-04-29	제넨테크, 인크.	Ｔｎｆ-알파 저해제에 대해 부적절한 반응을 하는 환자에서의 자가면역 질환의 치료법
TWI353991B (en)	2003-05-06	2011-12-11	Syntonix Pharmaceuticals Inc	Immunoglobulin chimeric monomer-dimer hybrids
CN1802388B (zh) *	2003-05-09	2011-01-05	杜克大学	Cd20特异抗体及使用它们的方法
US20050163775A1 (en) *	2003-06-05	2005-07-28	Genentech, Inc.	Combination therapy for B cell disorders
ES2538469T3 (es) *	2003-06-05	2015-06-22	Genentech, Inc.	Terapia de combinación para trastornos de células B
WO2004108065A2 (en) *	2003-06-09	2004-12-16	Insight Biopharmaceuticals Ltd.	Heparanase activity neutralizing anti- heparanase monoclonal antibody and other anti-heparanase antibodies
US7754209B2 (en)	2003-07-26	2010-07-13	Trubion Pharmaceuticals	Binding constructs and methods for use thereof
SI1648940T1 (sl)	2003-07-28	2016-08-31	Genentech, Inc.	Zmanjševanje izluževanja proteina A med afinitetno kromatografijo proteina A
CN1860367B (zh) *	2003-07-29	2010-05-26	健泰科生物技术公司	人抗cd20抗体的测定法及其用途
KR20060132554A (ko) *	2003-08-29	2006-12-21	제넨테크, 인크.	안과 질병의 항-ｃｄ２０ 치료
US8101720B2 (en) *	2004-10-21	2012-01-24	Xencor, Inc.	Immunoglobulin insertions, deletions and substitutions
US8399618B2 (en)	2004-10-21	2013-03-19	Xencor, Inc.	Immunoglobulin insertions, deletions, and substitutions
US8883147B2 (en)	2004-10-21	2014-11-11	Xencor, Inc.	Immunoglobulins insertions, deletions, and substitutions
US9714282B2 (en)	2003-09-26	2017-07-25	Xencor, Inc.	Optimized Fc variants and methods for their generation
US20060134105A1 (en) *	2004-10-21	2006-06-22	Xencor, Inc.	IgG immunoglobulin variants with optimized effector function
WO2005040220A1 (en)	2003-10-16	2005-05-06	Micromet Ag	Multispecific deimmunized cd3-binders
WO2005044307A2 (en)	2003-11-04	2005-05-19	Chiron Corporation	Methods of therapy for b cell-related cancers
LT2077282T (lt) *	2003-11-05	2017-03-10	Roche Glycart Ag	Antigeną surišančios molekulės su padidintu fc receptoriaus surišimo giminingumu ir efektoriaus funkcija
JP2007513072A (ja) *	2003-11-05	2007-05-24	パリンゲンインコーポレーテッド	Ｃｄｉｍ結合抗体における増強されたｂ細胞細胞傷害性
CA2545603A1 (en)	2003-11-12	2005-05-26	Biogen Idec Ma Inc.	Neonatal fc receptor (fcrn)-binding polypeptide variants, dimeric fc binding proteins and methods related thereto
WO2005060520A2 (en) *	2003-11-25	2005-07-07	Dana-Farber Cancer Institute, Inc.	ANTIBODIES AGAINST SARS-CoV AND METHODS OF USE THEREOF
CN1917901A (zh) *	2003-12-19	2007-02-21	健泰科生物技术公司	自身免疫病疗法中cd20的检测
MXPA06006865A (es) *	2003-12-19	2006-08-23	Genentech Inc	Deteccion de cd20 en rechazo de transplante.
FR2867982B1 (fr) *	2004-03-26	2007-07-20	Jean Marie Andrieu	Procede pour amplifier l'activite de vaccins therapeutiques
EP1745288A2 (en) *	2004-04-16	2007-01-24	Genentech, Inc.	Assay for antibodies
WO2005113003A2 (en) *	2004-04-16	2005-12-01	Genentech, Inc.	Method for augmenting b cell depletion
RU2006140374A (ru) *	2004-04-16	2008-05-27	Дженентек, Инк. (Us)	Лечение нарушений
US7850962B2 (en) *	2004-04-20	2010-12-14	Genmab A/S	Human monoclonal antibodies against CD20
EP1773393A2 (en) *	2004-05-05	2007-04-18	Genentech, Inc.	Preventing autoimmune disease by using an anti-cd20 antibody
JP4982373B2 (ja)	2004-05-20	2012-07-25	ザイモジェネティクス，インコーポレイテッド	Ｉｌ−２１およびモノクローナル抗体治療を用いる癌を処置する方法
PA8635501A1 (es) *	2004-06-04	2006-06-02	Genentech Inc	Uso de un anticuerpo para el tratamiento del lupus
BRPI0510915A (pt) *	2004-06-04	2007-11-13	Genentech Inc	método para o tratamento da esclerose múltipla e artigo manufaturado
US9109255B2 (en) *	2004-06-18	2015-08-18	The Board Of Trustees Of The Leland Stanford Junior University	Methods and compositions for determining responsiveness to antibody therapy
CN101014619B (zh)	2004-07-15	2010-11-03	赞科股份有限公司	优化的Fc变体
WO2006012508A2 (en) *	2004-07-22	2006-02-02	Genentech, Inc.	Method of treating sjögren's syndrome
ES2531155T3 (es)	2004-07-23	2015-03-11	Genentech Inc	Cristalización de anticuerpos anti-VEGF
US7740847B2 (en)	2004-08-04	2010-06-22	Applied Molecular Evolution, Inc.	Variant Fc regions
WO2006033732A1 (en) *	2004-08-17	2006-03-30	Invitrogen Corporation	Synthesis of highly luminescent colloidal particles
CA2577133A1 (en) *	2004-08-19	2006-03-23	Genentech, Inc.	Polypeptide variants with altered effector function
US7662926B2 (en) *	2004-09-02	2010-02-16	Genentech, Inc.	Anti-Fc-gamma receptor antibodies, bispecific variants and uses therefor
US7655229B2 (en) *	2004-09-02	2010-02-02	Chan Andrew C	Anti-FC-gamma RIIB receptor antibody and uses therefor
AU2005282720B2 (en) *	2004-09-02	2011-08-04	Genentech, Inc.	Anti-FC-gamma RIIB receptor antibody and uses therefor
WO2006029275A2 (en) *	2004-09-08	2006-03-16	Genentech, Inc.	Methods of using death receptor ligands and cd20 antibodies
JP2008513367A (ja) *	2004-09-08	2008-05-01	ジェネンテック・インコーポレーテッド	デスレセプターリガンド及びｃｄ２０抗体の使用方法
CN101087807A (zh) *	2004-10-05	2007-12-12	健泰科生物技术公司	治疗血管炎的方法
JO3000B1 (ar)	2004-10-20	2016-09-05	Genentech Inc	مركبات أجسام مضادة .
JP2008519108A (ja) *	2004-10-29	2008-06-05	モレキュラープローブス，インコーポレイテッド	官能化蛍光性ナノ結晶、並びにそれらの調製及び使用方法
US7632497B2 (en) *	2004-11-10	2009-12-15	Macrogenics, Inc.	Engineering Fc Antibody regions to confer effector function
US8802820B2 (en)	2004-11-12	2014-08-12	Xencor, Inc.	Fc variants with altered binding to FcRn
US8367805B2 (en) *	2004-11-12	2013-02-05	Xencor, Inc.	Fc variants with altered binding to FcRn
US8546543B2 (en)	2004-11-12	2013-10-01	Xencor, Inc.	Fc variants that extend antibody half-life
US20070135620A1 (en) *	2004-11-12	2007-06-14	Xencor, Inc.	Fc variants with altered binding to FcRn
WO2006053301A2 (en)	2004-11-12	2006-05-18	Xencor, Inc.	Fc variants with altered binding to fcrn
GB2420976B (en) *	2004-11-19	2006-12-20	Zvi Finkelstein	Therapeutic implant
SG158089A1 (en) *	2004-12-17	2010-01-29	Genentech Inc	Antiangiogenesis therapy of autoimmune disease in patients who have failed prior therapy
SG176509A1 (en)	2004-12-22	2011-12-29	Genentech Inc	Methods for producing soluble multi-membrane-spanning proteins
EP1674479A1 (en) *	2004-12-22	2006-06-28	Memorial Sloan-Kettering Cancer Center	Modulation of Fc Gamma receptors for optimizing immunotherapy
EP1674457B1 (en)	2004-12-23	2009-06-03	GPC Biotech AG	Derivatives of squaric acid with anti-proliferative activity
CA2589054C (en) *	2004-12-23	2010-11-02	F. Hoffmann-La Roche Ag	Detection of a therapeutic antibody in an experimental animal
WO2006074397A2 (en)	2005-01-05	2006-07-13	Biogen Idec Ma Inc.	Cripto binding molecules
WO2006076651A2 (en) *	2005-01-13	2006-07-20	Genentech, Inc.	Treatment method
DOP2006000029A (es) *	2005-02-07	2006-08-15	Genentech Inc	Antibody variants and uses thereof. (variantes de un anticuerpo y usos de las mismas)
TW200714289A (en) *	2005-02-28	2007-04-16	Genentech Inc	Treatment of bone disorders
US20160355591A1 (en)	2011-05-02	2016-12-08	Immunomedics, Inc.	Subcutaneous anti-hla-dr monoclonal antibody for treatment of hematologic malignancies
US8475794B2 (en)	2005-04-06	2013-07-02	Ibc Pharmaceuticals, Inc.	Combination therapy with anti-CD74 antibodies provides enhanced toxicity to malignancies, Autoimmune disease and other diseases
US8349332B2 (en)	2005-04-06	2013-01-08	Ibc Pharmaceuticals, Inc.	Multiple signaling pathways induced by hexavalent, monospecific and bispecific antibodies for enhanced toxicity to B-cell lymphomas and other diseases
US9284375B2 (en) *	2005-04-15	2016-03-15	Macrogenics, Inc.	Covalent diabodies and uses thereof
CA2605024C (en)	2005-04-15	2018-05-22	Macrogenics, Inc.	Covalent diabodies and uses thereof
US11254748B2 (en)	2005-04-15	2022-02-22	Macrogenics, Inc.	Covalent diabodies and uses thereof
AR053579A1 (es) *	2005-04-15	2007-05-09	Genentech Inc	Tratamiento de la enfermedad inflamatoria intestinal (eii)
US9963510B2 (en) *	2005-04-15	2018-05-08	Macrogenics, Inc.	Covalent diabodies and uses thereof
AU2006238812A1 (en) *	2005-04-22	2006-11-02	Genentech, Inc.	Method for treating dementia or Alzheimer's disease with a CD20 antibody
EP1885396A2 (en) *	2005-05-04	2008-02-13	Quark Pharmaceuticals, Inc.	Recombinant antibodies against cd55 and cd59 and uses thereof
US20070111281A1 (en) *	2005-05-09	2007-05-17	Glycart Biotechnology Ag	Antigen binding molecules having modified Fc regions and altered binding to Fc receptors
DE602006012839D1 (de) *	2005-05-20	2010-04-22	Genentech Inc	Vorbehandlung einer biologischen probe aus einem individuum mit autoimmunkrankheit
JP2009508467A (ja) *	2005-05-24	2009-03-05	アベスタゲンリミテッド	Ｂ細胞リンパ腫の治療のためのｃｄ２０に対するモノクローナル抗体を生成する方法
EP2238986A3 (en)	2005-07-08	2010-11-03	Biogen Idec MA Inc.	Sp35 antibodies and uses thereof
KR20080047540A (ko)	2005-07-25	2008-05-29	트루비온 파마슈티칼스, 인코포레이티드	Ｃｄ20 특이적 결합 분자의 단회 투여 용도
RU2423381C2 (ru)	2005-07-25	2011-07-10	Трабьон Фармасьютикалз, Инк.	Снижение количества в-клеток с использованием cd37-специфических и cd20-специфических связывающих молекул
US20080279850A1 (en) *	2005-07-25	2008-11-13	Trubion Pharmaceuticals, Inc.	B-Cell Reduction Using CD37-Specific and CD20-Specific Binding Molecules
WO2007021841A2 (en)	2005-08-10	2007-02-22	Macrogenics, Inc.	Identification and engineering of antibodies with variant fc regions and methods of using same
US20090215992A1 (en) *	2005-08-19	2009-08-27	Chengbin Wu	Dual variable domain immunoglobulin and uses thereof
EP2500357A3 (en)	2005-08-19	2012-10-24	Abbott Laboratories	Dual variable domain immunoglobulin and uses thereof
US7612181B2 (en) *	2005-08-19	2009-11-03	Abbott Laboratories	Dual variable domain immunoglobulin and uses thereof
WO2007024715A2 (en)	2005-08-19	2007-03-01	Abbott Laboratories	Dual variable domain immunoglobin and uses thereof
EP1942935A4 (en) *	2005-09-02	2009-12-23	Glycofi Inc	IMMUNOGLOBULINS COMPRISING MAINLY A GLYCOFORM GLCNACMAN3GLCNAC2
AU2006299429B2 (en)	2005-10-03	2012-02-23	Xencor, Inc.	Fc variants with optimized Fc receptor binding properties
WO2007056411A2 (en) *	2005-11-08	2007-05-18	Genentech, Inc.	Method of producing pan-specific antibodies
MY149159A (en)	2005-11-15	2013-07-31	Hoffmann La Roche	Method for treating joint damage
ES2618543T3 (es)	2005-11-23	2017-06-21	Genentech, Inc.	Métodos y composiciones relacionados con ensayos de linfocitos B
US20070136826A1 (en) *	2005-12-02	2007-06-14	Biogen Idec Inc.	Anti-mouse CD20 antibodies and uses thereof
US8323644B2 (en) *	2006-01-17	2012-12-04	Sloan-Kettering Institute For Cancer Research	Therapy-enhancing glucan
WO2007102200A1 (ja) *	2006-03-07	2007-09-13	Osaka University	抗ｃｄ２０モノクローナル抗体
JP2009529331A (ja) *	2006-03-10	2009-08-20	マクロジェニクス，インコーポレーテッド	変異型重鎖を有する抗体の同定および工学的改変ならびにその使用方法
EP2389950A1 (en)	2006-03-23	2011-11-30	Novartis AG	Anti-tumor cell antigen antibody therapeutics
EP2027291A2 (en)	2006-04-27	2009-02-25	Pikamab, Inc.	Methods and compositions for antibody therapy
US20080118978A1 (en)	2006-04-28	2008-05-22	Takashi Sato	Anti-tumor agent
US7727525B2 (en) *	2006-05-11	2010-06-01	City Of Hope	Engineered anti-CD20 antibody fragments for in vivo targeting and therapeutics
CA2660592C (en)	2006-05-26	2016-07-12	Macrogenics, Inc.	Humanized fc.gamma.riib-specific antibodies and methods of use thereof
CA2654317A1 (en) *	2006-06-12	2007-12-21	Trubion Pharmaceuticals, Inc.	Single-chain multivalent binding proteins with effector function
SI2029173T1 (sl)	2006-06-26	2016-12-30	Macrogenics, Inc.	Protitelesa, specifična za Fc RIIB, in postopki za njihovo uporabo
EP2032159B1 (en)	2006-06-26	2015-01-07	MacroGenics, Inc.	Combination of fcgammariib antibodies and cd20-specific antibodies and methods of use thereof
FR2902799B1 (fr)	2006-06-27	2012-10-26	Millipore Corp	Procede et unite de preparation d'un echantillon pour l'analyse microbiologique d'un liquide
US8636995B2 (en) *	2006-08-31	2014-01-28	Cardiac Pacemakers, Inc.	Methods and devices to regulate stem cell homing
US20080058922A1 (en) *	2006-08-31	2008-03-06	Cardiac Pacemakers, Inc.	Methods and devices employing vap-1 inhibitors
US8372399B2 (en) *	2006-08-31	2013-02-12	Cardiac Pacemakers, Inc.	Bispecific antibodies and agents to enhance stem cell homing
US20080112961A1 (en) *	2006-10-09	2008-05-15	Macrogenics, Inc.	Identification and Engineering of Antibodies with Variant Fc Regions and Methods of Using Same
US9382327B2 (en)	2006-10-10	2016-07-05	Vaccinex, Inc.	Anti-CD20 antibodies and methods of use
WO2008140603A2 (en)	2006-12-08	2008-11-20	Macrogenics, Inc.	METHODS FOR THE TREATMENT OF DISEASE USING IMMUNOGLOBULINS HAVING FC REGIONS WITH ALTERED AFFINITIES FOR FCγR ACTIVATING AND FCγR INHIBITING
US8569464B2 (en) *	2006-12-21	2013-10-29	Emd Millipore Corporation	Purification of proteins
US8362217B2 (en)	2006-12-21	2013-01-29	Emd Millipore Corporation	Purification of proteins
US20100267933A1 (en) *	2006-12-21	2010-10-21	Moya Wilson	Purification of proteins
KR20120017469A (ko)	2007-01-05	2012-02-28	유니버시티 오브 취리히	질환 특이적 결합 분자 및 표적을 제공하는 방법
DE102007001370A1 (de)	2007-01-09	2008-07-10	Curevac Gmbh	RNA-kodierte Antikörper
EP2068887B1 (en)	2007-01-09	2014-03-12	Biogen Idec MA Inc.	Sp35 antibodies and uses thereof
ES2374330T3 (es)	2007-01-22	2012-02-15	Genentech, Inc.	Precipitación con polielectrolito y purificación de anticuerpos.
US8450348B2 (en) *	2007-02-21	2013-05-28	Forma Tm, Llc	Derivatives of squaric acid with anti-proliferative activity
JP5622397B2 (ja)	2007-03-12	2014-11-12	エスバテック− アノバルティスカンパニーエルエルシー	一本鎖抗体の配列に基づく操作および最適化
US7960139B2 (en)	2007-03-23	2011-06-14	Academia Sinica	Alkynyl sugar analogs for the labeling and visualization of glycoconjugates in cells
WO2008122039A2 (en) *	2007-04-02	2008-10-09	The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Selenocysteine mediated hybrid antibody molecules
FR2915398B1 (fr) *	2007-04-25	2012-12-28	Lab Francais Du Fractionnement	"ensemble de moyens pour le traitement d'une pathologie maligne, d'une maladie auto-immune ou d'une maladie infectieuse"
EP1995309A1 (en) *	2007-05-21	2008-11-26	Vivalis	Recombinant protein production in avian EBx® cells
EP2019101A1 (en) *	2007-07-26	2009-01-28	GPC Biotech AG	Pyrazol[3,4-d]pyrimidin-4-one useful as Kinase Inhibitor
MX2009013327A (es) *	2007-06-25	2010-06-02	Esbatech An Alcon Biomedical R	Ingenieria basada en secuencias y optimizacion de anticuerpos de cadena simple.
KR101573086B1 (ko)	2007-06-25	2015-11-30	에스바테크 - 어 노바티스 컴파니 엘엘씨	항체를 변형시키는 방법, 및 기능적 특성이 개선된 변형된 항체
US10745701B2 (en)	2007-06-28	2020-08-18	The Trustees Of Princeton University	Methods of identifying and treating poor-prognosis cancers
US20090324596A1 (en) *	2008-06-30	2009-12-31	The Trustees Of Princeton University	Methods of identifying and treating poor-prognosis cancers
CN119241636A (zh)	2007-07-09	2025-01-03	健泰科生物技术公司	在多肽的重组生产期间防止二硫键还原
WO2009018411A1 (en) *	2007-07-31	2009-02-05	Regeneron Pharmaceuticals, Inc.	Human antibodies to human cd20 and method of using thereof
US20110243931A1 (en) *	2007-09-02	2011-10-06	Thomas Friess	Combination therapy with type i and type ii anti-cd20 antibodies
BRPI0817233A2 (pt) *	2007-09-28	2012-11-06	Intrexon Corp	construções terapêuticas de gene de trca e bireatores para a expressão de moléculas bioterapêuticas, e usos das mesmas
US20090098118A1 (en) *	2007-10-15	2009-04-16	Thomas Friess	Combination therapy of a type ii anti-cd20 antibody with an anti-bcl-2 active agent
HUE030134T2 (en)	2007-10-16	2017-04-28	Zymogenetics Inc	Combination of transmembrane activator and calcium modulator and cyclophilin ligand interactor (TACI) and anti-CD20 agents for the treatment of autoimmune diseases
CN101820892A (zh) *	2007-10-22	2010-09-01	昂科利蒂克斯生物科技公司	增殖性疾病的治疗方案
US20090110688A1 (en) *	2007-10-24	2009-04-30	Georg Fertig	Combination therapy of type ii anti-cd20 antibody with a proteasome inhibitor
CN101889025B (zh)	2007-10-30	2013-11-13	健泰科生物技术公司	通过阳离子交换层析进行的抗体纯化
WO2009117030A2 (en) *	2007-12-19	2009-09-24	Macrogenics, Inc.	Improved compositions for the prevention and treatment of smallpox
JP2011507897A (ja) *	2007-12-21	2011-03-10	ジェネンテック，インコーポレイテッド	リツキシマブ抵抗性関節リウマチ患者の治療
CA3147069A1 (en)	2007-12-26	2009-07-09	Xencor, Inc.	Fc variants with altered binding to fcrn
US7914785B2 (en)	2008-01-02	2011-03-29	Bergen Teknologieverforing As	B-cell depleting agents, like anti-CD20 antibodies or fragments thereof for the treatment of chronic fatigue syndrome
EP2077281A1 (en)	2008-01-02	2009-07-08	Bergen Teknologioverforing AS	Anti-CD20 antibodies or fragments thereof for the treatment of chronic fatigue syndrome
ATE548052T1 (de)	2008-01-17	2012-03-15	Philogen Spa	Kombination aus einem anti-edb-fibronectin- antikörper-il-2-fusionsprotein und einem b-zellen bindenden molekül, b-zellen-vorläufern und/oder deren krebserregendem gegenspieler
US20110033378A1 (en)	2008-01-18	2011-02-10	Medlmmune, Llc.	Cysteine Engineered Antibodies For Site-Specific Conjugation
US8883155B2 (en) *	2008-01-28	2014-11-11	The Regents Of The University Of California	Methods for treating hematopoietic malignancies
KR101280716B1 (ko) *	2008-03-25	2013-07-01	로슈 글리카트 아게	비-호지킨 림프종의 치료를 위한, 시클로포스파미드, 빈크리스틴 및 독소루비신과 조합으로의 증가된 항체 의존성 세포 세포독성 (ａｄｃｃ) 을 갖는 유형 ⅱ 항-ｃｄ20 항체의 용도
EP3045475B1 (en)	2008-04-02	2017-10-04	MacroGenics, Inc.	Bcr-complex-specific antibodies and methods of using same
CA2720368C (en)	2008-04-02	2017-08-22	Macrogenics, Inc.	Her2/neu-specific antibodies and methods of using same
EP2132228B1 (en) *	2008-04-11	2011-06-22	Emergent Product Development Seattle, LLC	Cd37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof
EP2112150B1 (en)	2008-04-22	2013-10-16	Forma Therapeutics, Inc.	Improved raf inhibitors
EP2112152A1 (en)	2008-04-22	2009-10-28	GPC Biotech AG	Dihydropteridinones as Plk Inhibitors
CN102076355B (zh)	2008-04-29	2014-05-07	Abbvie公司	双重可变结构域免疫球蛋白及其用途
US20090269339A1 (en) *	2008-04-29	2009-10-29	Genentech, Inc.	Responses to immunizations in rheumatoid arthritis patients treated with a cd20 antibody
US20100260668A1 (en) *	2008-04-29	2010-10-14	Abbott Laboratories	Dual Variable Domain Immunoglobulins and Uses Thereof
CN102112494A (zh) *	2008-06-03	2011-06-29	雅培制药有限公司	双重可变结构域免疫球蛋白及其用途
NZ589434A (en)	2008-06-03	2012-11-30	Abbott Lab	Dual variable domain immunoglobulins and uses thereof
EP2282770B1 (en) *	2008-06-04	2018-03-07	MacroGenics, Inc.	Antibodies with altered binding to fcrn and methods of using same
US8999702B2 (en) *	2008-06-11	2015-04-07	Emd Millipore Corporation	Stirred tank bioreactor
PL3241843T3 (pl)	2008-06-25	2021-12-27	Novartis Ag	Optymalizacja rozpuszczalności cząsteczek immunowiążących
KR101054362B1 (ko)	2008-07-03	2011-08-05	재단법인 목암생명공학연구소	재조합 단백질의 푸코스 함량을 감소시키는 방법
EP2310006A4 (en)	2008-07-03	2012-04-25	Mayo Foundation	CANCER TREATMENT
US8822645B2 (en) *	2008-07-08	2014-09-02	Abbvie Inc.	Prostaglandin E2 dual variable domain immunoglobulins and uses thereof
US8058406B2 (en)	2008-07-09	2011-11-15	Biogen Idec Ma Inc.	Composition comprising antibodies to LINGO or fragments thereof
KR101030978B1 (ko) *	2008-07-10	2011-04-28	(주) 에이프로젠	동물세포용 재조합 발현벡터
US20100021460A1 (en) *	2008-07-15	2010-01-28	Genentech, Inc.	Methods of Treating Autoimmune Diseases Using CD4 Antibodies
WO2010009271A2 (en)	2008-07-15	2010-01-21	Academia Sinica	Glycan arrays on ptfe-like aluminum coated glass slides and related methods
CN102159243B (zh) *	2008-07-21	2015-08-19	免疫医疗公司	用于改良的治疗特征的抗体的结构变体
WO2010011281A2 (en) *	2008-07-22	2010-01-28	The Research Foundation Of State University Of New York	Methods and compositions for the diagnosis and treatment of cancer
BRPI0823046B1 (pt)	2008-08-14	2021-12-14	Genentech, Inc	Método para purificar um anticorpo monoclonal de uma composição compreendendo o anticorpo monoclonal e pelo menos uma proteína de ovário de hamster chinês (chop)
US20100068210A1 (en)	2008-09-10	2010-03-18	Ji Junyan A	Compositions and methods for the prevention of oxidative degradation of proteins
TW201014605A (en)	2008-09-16	2010-04-16	Genentech Inc	Methods for treating progressive multiple sclerosis
AU2009309387A1 (en) *	2008-10-28	2010-05-06	Avesthagen Limited	An expression vector and processes thereof
US20100233079A1 (en) *	2008-12-04	2010-09-16	Abbott Laboratories	Dual Variable Domain Immunoglobulins and Uses Thereof
GB2466025A (en)	2008-12-08	2010-06-09	Univ Francois Rabelais De Tour	C3/ITGAM polymorphisms and cancer prognosis
EP2373689A1 (en)	2008-12-12	2011-10-12	MedImmune, LLC	Crystals and structure of a human igg fc variant with enhanced fcrn binding
SG171764A1 (en) *	2008-12-16	2011-07-28	Millipore Corp	Purification of proteins
SG171446A1 (en)	2008-12-16	2011-07-28	Millipore Corp	Stirred tank reactor and method
MX2011006422A (es)	2008-12-19	2011-09-15	Panima Pharmaceuticals Ag	Autoanticuerpos humanos anti-alfa-sinucleina.
WO2010075249A2 (en)	2008-12-22	2010-07-01	Genentech, Inc.	A method for treating rheumatoid arthritis with b-cell antagonists
JP5738196B2 (ja)	2008-12-22	2015-06-17	ミレニアムファーマシューティカルズ，インコーポレイテッドＭｉｌｌｅｎｎｉｕｍＰｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ．	オーロラキナーゼ阻害剤および抗ｃｄ２０抗体の併用
WO2010078526A1 (en)	2008-12-31	2010-07-08	Biogen Idec Ma Inc.	Anti-lymphotoxin antibodies
US20110142836A1 (en) *	2009-01-02	2011-06-16	Olav Mella	B-cell depleting agents for the treatment of chronic fatigue syndrome
KR20110117652A (ko)	2009-01-06	2011-10-27	인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔)	동맥경화증의 치료를 위한 ｂ세포 감소 제제
JP5713923B2 (ja)	2009-02-27	2015-05-07	ジェネンテック，インコーポレイテッド	タンパク質標識方法及び組成物
WO2010102251A2 (en)	2009-03-05	2010-09-10	Abbott Laboratories	Il-17 binding proteins
SI2406284T1 (sl)	2009-03-10	2017-01-31	Biogen Ma Inc.	Anti-bcma protitelesa
KR101781654B1 (ko)	2009-03-12	2017-09-25	제넨테크, 인크.	조혈 악성종양의 치료를 위한 포스포이노시티드 ３-키나제 억제제 화합물 및 화학요법제의 조합물
EP2233500A1 (en)	2009-03-20	2010-09-29	LFB Biotechnologies	Optimized Fc variants
AU2010228990A1 (en)	2009-03-24	2011-10-27	Teva Biopharmaceuticals Usa, Inc.	Humanized antibodies against LIGHT and uses thereof
US20100247484A1 (en)	2009-03-31	2010-09-30	Heinrich Barchet	Combination therapy of an afucosylated antibody and one or more of the cytokines gm csf, m csf and/or il3
US8815242B2 (en) *	2009-05-27	2014-08-26	Synageva Biopharma Corp.	Avian derived antibodies
WO2010145846A1 (en)	2009-06-15	2010-12-23	Bayer Bioscience N.V.	Nicotiana benthamiana plants deficient in xylosyltransferase activity
BRPI1015234A2 (pt)	2009-06-22	2018-02-20	Medimmune Llc	regiões fc projetadas para conjugação sítio específica.
WO2011000543A1 (en) *	2009-06-30	2011-01-06	Philochem Ag	Murine antibody display library
UY32808A (es) *	2009-07-29	2011-02-28	Abbott Lab	Inmunoglobulinas como dominio variable dual y usos de las mismas
KR20180010324A (ko)	2009-08-11	2018-01-30	제넨테크, 인크.	글루타민-비함유 세포 배양 배지에서의 단백질의 생성
EP2464380A1 (en)	2009-08-14	2012-06-20	Roche Glycart AG	Combination therapy of an afucosylated cd20 antibody with fludarabine and/or mitoxantrone
TWI409079B (zh)	2009-08-14	2013-09-21	Roche Glycart Ag	非典型岩藻醣化ｃｄ２０抗體與苯達莫斯汀（ｂｅｎｄａｍｕｓｔｉｎｅ）之組合療法
AU2010289527C1 (en)	2009-09-01	2014-10-30	Abbvie Inc.	Dual variable domain immunoglobulins and uses thereof
JP5787891B2 (ja)	2009-09-01	2015-09-30	ジェネンテック，インコーポレイテッド	改変されたプロテインａ溶離による向上したタンパク質精製
WO2011028952A1 (en)	2009-09-02	2011-03-10	Xencor, Inc.	Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
EP2473637B1 (en)	2009-09-03	2017-03-29	F. Hoffmann-La Roche AG	Methods for treating, diagnosing, and monitoring rheumatoid arthritis
AR078161A1 (es)	2009-09-11	2011-10-19	Hoffmann La Roche	Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento.
PT2486141T (pt)	2009-10-07	2018-05-09	Macrogenics Inc	Polipéptidos contendo uma região fc que apresenta uma função efectora melhorada, devido a modificações do grau de fucosilação, e métodos para a sua utilização
KR20140015139A (ko)	2009-10-15	2014-02-06	애브비 인코포레이티드	이원 가변 도메인 면역글로불린 및 이의 용도
JP5715634B2 (ja) *	2009-10-19	2015-05-13	エフ．ホフマン−ラロシュアーゲーＦ．Ｈｏｆｆｍａｎｎ−ＬａＲｏｃｈｅＡｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ	非交差反応性抗ＩｇＧ抗体
UY32979A (es) *	2009-10-28	2011-02-28	Abbott Lab	Inmunoglobulinas con dominio variable dual y usos de las mismas
EP2325185A1 (en)	2009-10-28	2011-05-25	GPC Biotech AG	Plk inhibitor
US10087236B2 (en)	2009-12-02	2018-10-02	Academia Sinica	Methods for modifying human antibodies by glycan engineering
US11377485B2 (en)	2009-12-02	2022-07-05	Academia Sinica	Methods for modifying human antibodies by glycan engineering
US20110189178A1 (en) *	2010-02-04	2011-08-04	Xencor, Inc.	Immunoprotection of Therapeutic Moieties Using Enhanced Fc Regions
EP2531592A1 (en)	2010-02-04	2012-12-12	Vivalis	Fed-batch process using concentrated cell culture medium for the efficient production of biologics in eb66 cells
WO2011097527A2 (en)	2010-02-04	2011-08-11	Xencor, Inc.	Immunoprotection of therapeutic moieties using enhanced fc regions
AR080154A1 (es)	2010-02-10	2012-03-14	Immunogen Inc	Anticuerpos cd20 y su utilizacion
WO2011100398A1 (en) *	2010-02-10	2011-08-18	Immunogen, Inc.	Cd20 antibodies and uses thereof
ES2602971T3 (es)	2010-03-02	2017-02-23	Kyowa Hakko Kirin Co., Ltd.	Composición de anticuerpo modificado
PH12012501751A1 (en)	2010-03-04	2012-11-12	Macrogenics Inc	Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
PE20170779A1 (es)	2010-03-04	2017-07-04	Macrogenics Inc	Anticuerpos reactivos con b7-h3, fragmentos inmunologicamente activos de los mismos y usos de los mismos
MX354867B (es)	2010-03-22	2018-03-23	Genentech Inc Star	Composiciones y métodos útiles para estabilizar formulaciones que contienen proteína.
WO2011118739A1 (ja)	2010-03-26	2011-09-29	協和発酵キリン株式会社	新規修飾部位導入抗体および抗体フラグメント
EP3222632A1 (en)	2010-03-26	2017-09-27	Memorial Sloan-Kettering Cancer Center	Antibodies to muc16 and methods of use thereof
CN102971340A (zh)	2010-03-29	2013-03-13	酵活有限公司	具有增强的或抑制的效应子功能的抗体
WO2011123813A2 (en)	2010-04-02	2011-10-06	Amunix Operating Inc.	Binding fusion proteins, binding fusion protein-drug conjugates, xten-drug conjugates and methods of making and using same
WO2011130332A1 (en)	2010-04-12	2011-10-20	Academia Sinica	Glycan arrays for high throughput screening of viruses
BR112012026707A2 (pt)	2010-04-27	2017-03-14	Roche Glycart Ag	uso de um anticorpo anti-cd20 afucosilado, composição que compreende um anticorpo anti-cd20 afucosilado e método de tratamento de pacientes que sofrem de câncer por meio da administração de um anticorpo anti-cd20 afucosilado
JP2013525484A (ja)	2010-05-03	2013-06-20	ジェネンテック，インコーポレイテッド	タンパク質含有製剤の粘度を低減させるために有用な組成物及び方法
US9403855B2 (en)	2010-05-10	2016-08-02	Academia Sinica	Zanamivir phosphonate congeners with anti-influenza activity and determining oseltamivir susceptibility of influenza viruses
MY161302A (en)	2010-05-14	2017-04-14	Abbvie Inc	IL-1 binding proteins
SG10201804385YA (en)	2010-05-17	2018-06-28	Emd Millipore Corp	Stimulus responsive polymers for the purification of biomolecules
KR101976853B1 (ko)	2010-05-25	2019-05-09	제넨테크, 인크.	폴리펩티드의 정제 방법
SI2576580T1 (sl)	2010-05-28	2016-12-30	F. Hoffmann-La Roche Ag	Znižanje nivoja laktata in zvišanje produkcije polipeptida z znižanjem ravni izražanja laktat-dehidrogenaze in piruvat-dehidrogenaza-kinaze
SI2585045T1 (sl)	2010-06-24	2019-11-29	Hoffmann La Roche	Sestavki in postopki, ki vsebujejo alkilglikozide za stabilizacijo formulacij, ki vsebujejo beljakovine
WO2012006500A2 (en)	2010-07-08	2012-01-12	Abbott Laboratories	Monoclonal antibodies against hepatitis c virus core protein
UY33492A (es)	2010-07-09	2012-01-31	Abbott Lab	Inmunoglobulinas con dominio variable dual y usos de las mismas
US20130216513A1 (en)	2010-07-09	2013-08-22	Biogen Idec Hemophilia Inc.	Chimeric Clotting Factors
EP2409993A1 (en)	2010-07-19	2012-01-25	International-Drug-Development-Biotech	Anti-CD19 antibody having ADCC function with improved glycosylation profile
EP2409712A1 (en)	2010-07-19	2012-01-25	International-Drug-Development-Biotech	Anti-CD19 antibody having ADCC and CDC functions and improved glycosylation profile
CN103052649B (zh)	2010-07-29	2015-12-16	Xencor公司	具有修改的等电点的抗体
WO2012017925A1 (ja)	2010-08-02	2012-02-09	協和発酵キリン株式会社	物質の製造方法
SG187682A1 (en)	2010-08-02	2013-03-28	Macrogenics Inc	Covalent diabodies and uses thereof
RU2013109275A (ru)	2010-08-03	2014-09-10	Эббви Инк.	Иммуноглобулины с двумя вариабельными доменами и их применение
KR20130045914A (ko)	2010-08-03	2013-05-06	에프. 호프만-라 로슈 아게	만성 림프구성 백혈병(cll) 생체지표
US8822663B2 (en)	2010-08-06	2014-09-02	Moderna Therapeutics, Inc.	Engineered nucleic acids and methods of use thereof
KR20130100125A (ko)	2010-08-13	2013-09-09	제넨테크, 인크.	질환의 치료를 위한, ＩＬ-1β 및 ＩＬ-18에 대한 항체
TW201208703A (en)	2010-08-17	2012-03-01	Roche Glycart Ag	Combination therapy of an afucosylated CD20 antibody with an anti-VEGF antibody
CN103068852B (zh) *	2010-08-17	2016-04-20	弗·哈夫曼-拉罗切有限公司	抗人IgG1抗体
CA2809433A1 (en)	2010-08-26	2012-03-01	Abbvie Inc.	Dual variable domain immunoglobulins and uses thereof
WO2012030512A1 (en)	2010-09-03	2012-03-08	Percivia Llc.	Flow-through protein purification process
MX2013003681A (es)	2010-10-01	2013-11-20	Moderna Therapeutics Inc	Ácidos nucleicos manipulados y métodos de uso de los mismos.
NZ609984A (en)	2010-10-11	2015-05-29	Biogen Idec Internat Neuroscience Gmbh	Human anti-tau antibodies
JP2013541594A (ja)	2010-11-08	2013-11-14	ジェネンテック，インコーポレイテッド	皮下投与される抗ｉｌ−６受容体抗体
TR201802431T4 (tr)	2010-12-15	2018-03-21	Inter Univ Research Institute Corporation Research Organization Of Information And Systems	Protein üretme usulü.
EP2651976A1 (en)	2010-12-16	2013-10-23	Roche Glycart AG	Combination therapy of an afucosylated cd20 antibody with a mdm2 inhibitor
US9283271B2 (en)	2010-12-17	2016-03-15	Neurimmune Holding Ag	Human anti-SOD1 antibodies
CA2821976A1 (en)	2010-12-21	2012-09-13	Abbvie Inc.	Il-1 -alpha and -beta bispecific dual variable domain immunoglobulins and their use
WO2012091023A1 (ja)	2010-12-27	2012-07-05	協和発酵キリン株式会社	培地およびキレート剤を含む水溶液の調製方法
WO2012095514A1 (en)	2011-01-14	2012-07-19	Vivalis	Recombinant protein production system
US9433686B2 (en)	2011-01-31	2016-09-06	The Regents Of The University Of California	Methods for treating castration resistant prostate cancer and metastasis by reducing B-cell number and/or function
CA2827859A1 (en)	2011-02-28	2012-09-07	Genentech, Inc.	Biological markers and methods for predicting response to b-cell antagonists
TWI622597B (zh)	2011-03-28	2018-05-01	賽諾菲公司	具有交叉結合區定向之雙重可變區類抗體結合蛋白
SI2691417T1 (sl)	2011-03-29	2018-11-30	Roche Glycart Ag	FC variante protitelesa
JP2014511687A (ja)	2011-03-31	2014-05-19	モデルナセラピューティクスインコーポレイテッド	工学操作された核酸の送達および製剤
EP2506015A1 (en)	2011-04-01	2012-10-03	Universität Regensburg	A prognostic and therapeutic signature for malignant melanoma
WO2012145183A2 (en)	2011-04-19	2012-10-26	Pfizer Inc.	Combinations of anti-4-1bb antibodies and adcc-inducing antibodies for the treatment of cancer
LT2707030T (lt)	2011-05-09	2020-07-10	Mayo Foundation For Medical Education And Research	Vėžio gydymas
ES2567276T3 (es)	2011-05-12	2016-04-21	Genentech, Inc.	Método de LC-MS/MS de monitoreo de múltiples reacciones para detectar anticuerpos terapéuticos en muestras de animales usando péptidos de cambio de marco
CN107936121B (zh)	2011-05-16	2022-01-14	埃泰美德(香港)有限公司	多特异性fab融合蛋白及其使用方法
EA201391753A1 (ru)	2011-05-21	2014-08-29	Макродженикс, Инк.	Домены, связывающиеся с деиммунизованной сывороткой, и их применение для увеличения времени полужизни в сыворотке
HUE044209T2 (hu)	2011-05-21	2019-10-28	Macrogenics Inc	Humán és nem humán CD3-hoz kötõdni képes CD3-kötõ molekulák
RU2011122942A (ru)	2011-06-08	2012-12-20	Общество С Ограниченной Ответственностью "Асинэкс Медхим"	Новые ингибиторы киназ
EP2723379B1 (en)	2011-06-23	2018-09-12	Biogen International Neuroscience GmbH	Anti-alpha synuclein binding molecules
EP2537933A1 (en)	2011-06-24	2012-12-26	Institut National de la Santé et de la Recherche Médicale (INSERM)	An IL-15 and IL-15Ralpha sushi domain based immunocytokines
US20140234298A1 (en)	2011-07-06	2014-08-21	Morphosys Ag	Therapeutic combinations of anti-cd20 and anti-gm-csf antibodies and uses thereof
EP2732021B1 (en)	2011-07-08	2020-05-27	EMD Millipore Corporation	Improved depth filters for disposable biotechnological processes
WO2013009868A1 (en)	2011-07-11	2013-01-17	Yale University	Compositions and methods for making selenocysteine containing polypeptides
WO2019071023A1 (en)	2017-10-04	2019-04-11	Yale University	COMPOSITIONS AND METHODS FOR MAKING POLYPEPTIDES CONTAINING SELENOCYSTEINE
US9738707B2 (en)	2011-07-15	2017-08-22	Biogen Ma Inc.	Heterodimeric Fc regions, binding molecules comprising same, and methods relating thereto
EP2551348B1 (en)	2011-07-29	2014-09-24	Icon Genetics GmbH	Production of galactosylated N-glycans in plants
EP2550975A1 (en)	2011-07-29	2013-01-30	Sanofi	Combination therapy for the treatment of CD19+ B-cell malignancies symptoms comprising an anti-CD19 maytansinoid immunoconjugate and rituximab
WO2013022855A1 (en)	2011-08-05	2013-02-14	Xencor, Inc.	Antibodies with modified isoelectric points and immunofiltering
US9464124B2 (en)	2011-09-12	2016-10-11	Moderna Therapeutics, Inc.	Engineered nucleic acids and methods of use thereof
WO2013049362A2 (en)	2011-09-27	2013-04-04	The United States Of America, As Represented By The Secretary, Department Of Health & Human Services	Method of treating multiple sclerosis by intrathecal depletion of b cells and biomarkers to select patients with progressive multiple sclerosis
EP2763701B1 (en)	2011-10-03	2018-12-19	Moderna Therapeutics, Inc.	Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
US10196664B2 (en)	2011-10-04	2019-02-05	Icon Genetics Gmbh	Nicotiana benthamiana plants deficient in fucosyltransferase activity
EP2766392B1 (en)	2011-10-10	2019-07-17	Xencor, Inc.	A method for purifying antibodies
US10851178B2 (en)	2011-10-10	2020-12-01	Xencor, Inc.	Heterodimeric human IgG1 polypeptides with isoelectric point modifications
CA2853258A1 (en)	2011-10-24	2013-05-02	Abbvie Inc.	Immunobinders directed against sclerostin
BR112014010008A2 (pt)	2011-10-26	2018-09-04	Novartis Ag	anticorpos monoclonais, seus usos e ácidos nucleicos
US20130302274A1 (en)	2011-11-25	2013-11-14	Roche Glycart Ag	Combination therapy
CA3018046A1 (en)	2011-12-16	2013-06-20	Moderna Therapeutics, Inc.	Modified nucleoside, nucleotide, and nucleic acid compositions
AU2012355356B2 (en)	2011-12-22	2017-10-12	Genentech, Inc.	Ion exchange membrane chromatography
JP2015508994A (ja)	2011-12-30	2015-03-26	アッヴィ・インコーポレイテッド	Ｉｌ−１３および／またはｉｌ−１７に対する二重可変ドメイン免疫グロブリン
US20130243750A1 (en)	2012-01-31	2013-09-19	Genentech, Inc.	Anti-ige antibodies and methods using same
RU2659423C2 (ru)	2012-02-16	2018-07-02	ЭйТИР ФАРМА, ИНК.	ГИСТИДИЛ-тРНК-СИНТЕТАЗЫ ДЛЯ ЛЕЧЕНИЯ АУТОИММУННЫХ И ВОСПАЛИТЕЛЬНЫХ ЗАБОЛЕВАНИЙ
CA2866753C (en)	2012-03-27	2020-09-22	Genentech, Inc.	Improved harvest operations for recombinant proteins
DE18200782T1 (de)	2012-04-02	2021-10-21	Modernatx, Inc.	Modifizierte polynukleotide zur herstellung von proteinen im zusammenhang mit erkrankungen beim menschen
US10501512B2 (en)	2012-04-02	2019-12-10	Modernatx, Inc.	Modified polynucleotides
US9283287B2 (en)	2012-04-02	2016-03-15	Moderna Therapeutics, Inc.	Modified polynucleotides for the production of nuclear proteins
US9572897B2 (en)	2012-04-02	2017-02-21	Modernatx, Inc.	Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US10130714B2 (en)	2012-04-14	2018-11-20	Academia Sinica	Enhanced anti-influenza agents conjugated with anti-inflammatory activity
CA2873623C (en)	2012-05-14	2021-11-09	Biogen Idec Ma Inc.	Lingo-2 antagonists for treatment of conditions involving motor neurons
US10202595B2 (en)	2012-06-08	2019-02-12	Bioverativ Therapeutics Inc.	Chimeric clotting factors
JP6498600B2 (ja)	2012-06-08	2019-04-10	ストロバイオファーマインコーポレーテッド	部位特異的な非天然アミノ酸残基を含む抗体、その調製方法、及びその使用方法
TW201402608A (zh)	2012-07-12	2014-01-16	Abbvie Inc	Ｉｌ－１結合蛋白質
EP2872534B1 (en)	2012-07-13	2018-08-08	Roche Glycart AG	Bispecific anti-vegf/anti-ang-2 antibodies and their use in the treatment of ocular vascular diseases
JP6302909B2 (ja)	2012-08-18	2018-03-28	アカデミアシニカＡｃａｄｅｍｉａＳｉｎｉｃａ	シアリダーゼの同定および画像化のための細胞透過性プローブ
CA2883168A1 (en)	2012-08-21	2014-02-27	Academia Sinica	Benzocyclooctyne compounds and uses thereof
WO2014036492A1 (en)	2012-08-31	2014-03-06	Sutro Biopharma, Inc.	Modified amino acids comprising an azido group
JOP20200236A1 (ar)	2012-09-21	2017-06-16	Regeneron Pharma	الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
US9777067B2 (en)	2012-09-27	2017-10-03	Massachusetts Institute Of Technology	HER2- and VEGF-A-binding proteins with enhanced stability
AU2013327638B2 (en)	2012-10-01	2018-06-14	Mayo Foundation For Medical Education And Research	Cancer treatments
EP2906240A2 (en)	2012-10-09	2015-08-19	Biogen MA Inc.	Combination therapies and uses for treatment of demyelinating disorders
ME03486B (me)	2012-10-12	2020-01-20	Medimmune Ltd	Pirolobenzodiazepini i njihovi konjugati
TW202037609A (zh)	2012-11-01	2020-10-16	美商艾伯維有限公司	抗-vegf/dll4雙重可變區域免疫球蛋白及其用途
SG10201802044RA (en)	2012-11-01	2018-05-30	Abbvie Inc	Stable dual variable domain immunoglobulin protein formulations
CN110269941A (zh)	2012-11-02	2019-09-24	Tg疗法有限公司	抗cd20抗体和pi3激酶选择性抑制剂的组合
JP6144355B2 (ja)	2012-11-26	2017-06-07	モデルナティエックスインコーポレイテッドＭｏｄｅｒｎａＴＸ，Ｉｎｃ．	化学修飾ｍＲＮＡ
WO2014100095A1 (en)	2012-12-19	2014-06-26	Genentech, Inc.	Methods and compositions for radiohalogen protein labeling
WO2014100600A2 (en)	2012-12-21	2014-06-26	Biogen Idec Ma Inc.	Human anti-tau antibodies
CN104936980B (zh)	2012-12-31	2019-06-07	生物控股有限公司	用于治疗和预防多瘤病毒相关的疾病的重组人抗体
US9701759B2 (en)	2013-01-14	2017-07-11	Xencor, Inc.	Heterodimeric proteins
US10968276B2 (en)	2013-03-12	2021-04-06	Xencor, Inc.	Optimized anti-CD3 variable regions
US9605084B2 (en)	2013-03-15	2017-03-28	Xencor, Inc.	Heterodimeric proteins
DK2943511T3 (da)	2013-01-14	2019-10-21	Xencor Inc	Nye heterodimeriske proteiner
US11053316B2 (en)	2013-01-14	2021-07-06	Xencor, Inc.	Optimized antibody variable regions
US10487155B2 (en)	2013-01-14	2019-11-26	Xencor, Inc.	Heterodimeric proteins
US10131710B2 (en)	2013-01-14	2018-11-20	Xencor, Inc.	Optimized antibody variable regions
US9738722B2 (en)	2013-01-15	2017-08-22	Xencor, Inc.	Rapid clearance of antigen complexes using novel antibodies
EP2949789B1 (en)	2013-01-24	2021-07-28	AbTLAS Co., Ltd.	Protein combination-based fv library, and preparation method therefor
WO2014124227A1 (en)	2013-02-07	2014-08-14	Immunomedics, Inc.	Pro-drug form (p2pdox) of the highly potent 2-pyrrolinodoxorubicin conjugated to antibodies for targeted therapy of cancer
EP4223772A3 (en)	2013-02-15	2023-10-18	Bioverativ Therapeutics Inc.	Optimized factor viii gene
US9487587B2 (en)	2013-03-05	2016-11-08	Macrogenics, Inc.	Bispecific molecules that are immunoreactive with immune effector cells of a companion animal that express an activating receptor and cells that express B7-H3 and uses thereof
MX365567B (es)	2013-03-13	2019-06-07	Genentech Inc	Formulaciones de anticuerpo.
ES2687439T3 (es)	2013-03-13	2018-10-25	Medimmune Limited	Pirrolobenzodiazepinas y conjugados de las mismas
DK2968520T3 (da)	2013-03-14	2021-08-09	Macrogenics Inc	Bispecifikke molekyler som er immunoreaktive med immuneffektorceller der udtrykker en aktiverende receptor
JP6387392B2 (ja)	2013-03-15	2018-09-05	バイオベラティブセラピューティクスインコーポレイテッド	第ｉｘ因子ポリペプチド製剤
EP2970459A2 (en)	2013-03-15	2016-01-20	AbbVie Inc.	Dual specific binding proteins directed against il-1beta and il-17
US10106624B2 (en)	2013-03-15	2018-10-23	Xencor, Inc.	Heterodimeric proteins
US8980864B2 (en)	2013-03-15	2015-03-17	Moderna Therapeutics, Inc.	Compositions and methods of altering cholesterol levels
US10519242B2 (en)	2013-03-15	2019-12-31	Xencor, Inc.	Targeting regulatory T cells with heterodimeric proteins
US10858417B2 (en)	2013-03-15	2020-12-08	Xencor, Inc.	Heterodimeric proteins
CA3093606A1 (en)	2013-03-15	2014-09-18	Xencor, Inc.	Heterodimeric proteins for induction of t cells
WO2014144960A2 (en)	2013-03-15	2014-09-18	Abbvie Biotherapeutics Inc.	Fc variants
CA2908380A1 (en)	2013-04-09	2014-10-16	Boston Biomedical, Inc.	Methods for treating cancer
HUE058364T2 (hu)	2013-04-19	2022-07-28	Cytune Pharma	Citokinbõl származó kezelés redukált vaszkuláris permeabilitási szindrómával
EP2805730A1 (en)	2013-05-21	2014-11-26	Bergen Teknologioverforing AS	Nitric oxide donor for the treatment of chronic fatigue syndrome
RU2655439C2 (ru)	2013-05-31	2018-05-28	Займворкс Инк.	Гетеромультимеры с уменьшенной или подавленной эффекторной функцией
WO2014210397A1 (en)	2013-06-26	2014-12-31	Academia Sinica	Rm2 antigens and use thereof
WO2014210564A1 (en)	2013-06-27	2014-12-31	Academia Sinica	Glycan conjugates and use thereof
EP3019522B1 (en)	2013-07-10	2017-12-13	Sutro Biopharma, Inc.	Antibodies comprising multiple site-specific non-natural amino acid residues, methods of their preparation and methods of their use
US11384149B2 (en)	2013-08-09	2022-07-12	Macrogenics, Inc.	Bi-specific monovalent Fc diabodies that are capable of binding CD32B and CD79b and uses thereof
UA116479C2 (uk)	2013-08-09	2018-03-26	Макродженікс, Інк.	БІСПЕЦИФІЧНЕ МОНОВАЛЕНТНЕ Fc-ДІАТІЛО, ЯКЕ ОДНОЧАСНО ЗВ'ЯЗУЄ CD32B I CD79b, ТА ЙОГО ЗАСТОСУВАННЯ
EP2839842A1 (en)	2013-08-23	2015-02-25	MacroGenics, Inc.	Bi-specific monovalent diabodies that are capable of binding CD123 and CD3 and uses thereof
EP2840091A1 (en)	2013-08-23	2015-02-25	MacroGenics, Inc.	Bi-specific diabodies that are capable of binding gpA33 and CD3 and uses thereof
WO2015035044A2 (en)	2013-09-04	2015-03-12	Abbvie Biotherapeutics Inc.	Fc VARIANTS WITH IMPROVED ANTIBODY-DEPENDENT CELL-MEDIATED CYTOTOXICITY
JP6486368B2 (ja)	2013-09-06	2019-03-20	アカデミアシニカＡｃａｄｅｍｉａＳｉｎｉｃａ	改変されたグリコシル基を含む糖脂質を用いたヒトｉＮＫＴ細胞の活性化
IL312865B1 (en)	2013-09-11	2025-02-01	Eagle Biologics Inc	Liquid protein formulations containing viscosity-reducing agents
WO2015048744A2 (en)	2013-09-30	2015-04-02	Moderna Therapeutics, Inc.	Polynucleotides encoding immune modulating polypeptides
BR112016007255A2 (pt)	2013-10-03	2017-09-12	Moderna Therapeutics Inc	polinucleotídeos que codificam receptor de lipoproteína de baixa densidade
WO2015054658A1 (en)	2013-10-11	2015-04-16	Sutro Biopharma, Inc.	Modified amino acids comprising tetrazine functional groups, methods of preparation, and methods of their use
WO2015063287A1 (en)	2013-11-01	2015-05-07	Bergen Teknologioverføring As	Activators or stimulators of soluble guanylate cyclase for use in treating chronic fatigue syndrome
CA2963178C (en)	2013-11-12	2023-01-24	Ogd2 Pharma	Human igg1 derived antibody with pro-apoptotic activity
WO2015095410A1 (en)	2013-12-17	2015-06-25	Genentech, Inc.	Methods of treating cancer using pd-1 axis binding antagonists and an anti-cd20 antibody
US10150818B2 (en)	2014-01-16	2018-12-11	Academia Sinica	Compositions and methods for treatment and detection of cancers
WO2015109180A2 (en)	2014-01-16	2015-07-23	Academia Sinica	Compositions and methods for treatment and detection of cancers
CA2935748A1 (en)	2014-02-25	2015-09-03	Immunomedics, Inc.	Humanized rfb4 anti-cd22 antibody
EP2915569A1 (en)	2014-03-03	2015-09-09	Cytune Pharma	IL-15/IL-15Ralpha based conjugates purification method
TWI701042B (zh)	2014-03-19	2020-08-11	美商再生元醫藥公司	用於腫瘤治療之方法及抗體組成物
JP6562942B2 (ja)	2014-03-27	2019-08-28	アカデミアシニカＡｃａｄｅｍｉａＳｉｎｉｃａ	反応性標識化合物およびその使用
DK3122781T3 (da)	2014-03-28	2020-03-16	Xencor Inc	Bispecifikke antistoffer, der binder til cd38 og cd3
PL4219687T3 (pl)	2014-04-23	2024-10-28	Juno Therapeutics, Inc.	Metody izolacji, hodowli i inżynierii genetycznej populacji komórek odpornościowych na potrzeby terapii adopcyjnej
US20170049887A1 (en)	2014-04-25	2017-02-23	University Of Florida Research Foundation, Inc.	Methods of permitting a subject to receive multiple doses of recombinant adeno-associated virus
TWI670078B (zh)	2014-05-27	2019-09-01	中央研究院	抗ｃｄ２０醣抗體及其用途
WO2015184002A1 (en)	2014-05-27	2015-12-03	Academia Sinica	Anti-her2 glycoantibodies and uses thereof
US10118969B2 (en)	2014-05-27	2018-11-06	Academia Sinica	Compositions and methods relating to universal glycoforms for enhanced antibody efficacy
CN106661562A (zh)	2014-05-27	2017-05-10	中央研究院	得自类杆菌属的岩藻糖苷酶及其用途
US11332523B2 (en)	2014-05-28	2022-05-17	Academia Sinica	Anti-TNF-alpha glycoantibodies and uses thereof
CN113318239A (zh)	2014-06-13	2021-08-31	梅约医药教育及研究基金会	治疗淋巴瘤
CA2952424C (en)	2014-06-16	2019-07-23	Mayo Foundation For Medical Education And Research	Treating myelomas
WO2016004113A1 (en)	2014-06-30	2016-01-07	Biogen Ma Inc.	Optimized factor ix gene
CA2953154C (en)	2014-07-09	2023-03-14	Genentech, Inc.	Ph adjustment to improve thaw recovery of cell banks
JP2017522886A (ja)	2014-07-29	2017-08-17	ニューリミューンホールディングエイジー	ヒト由来抗ハンチンチン（ｈｔｔ）抗体及びその使用
EP3191500A4 (en)	2014-09-08	2018-04-11	Academia Sinica	HUMAN iNKT CELL ACTIVATION USING GLYCOLIPIDS
US10188746B2 (en)	2014-09-10	2019-01-29	Medimmune Limited	Pyrrolobenzodiazepines and conjugates thereof
CN114181312A (zh)	2014-09-10	2022-03-15	豪夫迈·罗氏有限公司	半乳糖改造的免疫球蛋白1抗体
AU2015318001B2 (en)	2014-09-15	2021-03-25	Genentech, Inc.	Antibody formulations
HRP20200924T8 (hr)	2014-09-23	2023-07-21	F. Hoffmann - La Roche Ag	Postupak primjene imunokonjugata anti-cd79b
AU2015323860B2 (en)	2014-09-29	2021-05-27	Duke University	Bispecific molecules comprising an HIV-1 envelope targeting arm
BR112017006598A2 (pt)	2014-09-30	2018-04-17	Neurimmune Holding Ag	anticorpo de repetições antidipeptídeo derivado de ser humano (dprs)
SG11201702614SA (en)	2014-10-01	2017-04-27	Eagle Biolog Inc	Polysaccharide and nucleic acid formulations containing viscosity-lowering agents
US9446148B2 (en)	2014-10-06	2016-09-20	Mayo Foundation For Medical Education And Research	Carrier-antibody compositions and methods of making and using the same
MA40835A (fr)	2014-10-23	2017-08-29	Biogen Ma Inc	Anticorps anti-gpiib/iiia et leurs utilisations
MA40861A (fr)	2014-10-31	2017-09-05	Biogen Ma Inc	Anticorps anti-glycoprotéines iib/iiia
MX385543B (es)	2014-11-17	2025-03-18	Regeneron Pharma	Uso de un anticuerpo biespecífico para tratar cáncer de linfocitos b.
US10889653B2 (en)	2014-11-26	2021-01-12	Xencor, Inc.	Heterodimeric antibodies that bind CD3 and tumor antigens
US10259887B2 (en)	2014-11-26	2019-04-16	Xencor, Inc.	Heterodimeric antibodies that bind CD3 and tumor antigens
MX2017006918A (es)	2014-11-26	2018-01-25	Xencor Inc	Anticuerpos heterodimericos que se unen a cd3 y cd38.
US10093733B2 (en)	2014-12-11	2018-10-09	Abbvie Inc.	LRP-8 binding dual variable domain immunoglobulin proteins
US10428155B2 (en)	2014-12-22	2019-10-01	Xencor, Inc.	Trispecific antibodies
JP2018504400A (ja)	2015-01-08	2018-02-15	バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎＭＡＩｎｃ．	Ｌｉｎｇｏ‐１拮抗薬及び脱髄障害の治療のための使用
US10495645B2 (en)	2015-01-16	2019-12-03	Academia Sinica	Cancer markers and methods of use thereof
US9975965B2 (en)	2015-01-16	2018-05-22	Academia Sinica	Compositions and methods for treatment and detection of cancers
TWI736523B (zh)	2015-01-24	2021-08-21	中央研究院	新穎聚醣結合物及其使用方法
US10227411B2 (en)	2015-03-05	2019-03-12	Xencor, Inc.	Modulation of T cells with bispecific antibodies and FC fusions
US10722523B2 (en)	2015-03-17	2020-07-28	The Regents Of The University Of California	Chemoimmunotherapy for epithelial cancer
CN107667120B (zh)	2015-03-17	2022-03-08	纪念斯隆-凯特林癌症中心	抗muc16抗体及其应用
EP4238994A3 (en)	2015-05-11	2024-02-07	F. Hoffmann-La Roche AG	Compositions and methods of treating lupus nephritis
SI3303373T1 (sl)	2015-05-30	2020-07-31	Molecular Templates, Inc.	Deimunizirana ogrodja A podenot Shiga toksina in celice-ciljajoče molekule, ki jih obsegajo
EA201792623A1 (ru)	2015-06-03	2018-04-30	Бостон Биомедикал, Инк.	Композиции, содержащие ингибитор стволовости рака и иммунотерапевтический агент, для применения в лечении рака
TW201710286A (zh)	2015-06-15	2017-03-16	艾伯維有限公司	抗ｖｅｇｆ、ｐｄｇｆ及／或其受體之結合蛋白
EP3108897A1 (en)	2015-06-24	2016-12-28	F. Hoffmann-La Roche AG	Antibodies against human csf-1r for use in inducing lymphocytosis in lymphomas or leukemias
CN113999312A (zh)	2015-06-24	2022-02-01	豪夫迈·罗氏有限公司	具有定制亲和力的抗转铁蛋白受体抗体
CA2989936A1 (en)	2015-06-29	2017-01-05	Genentech, Inc.	Type ii anti-cd20 antibody for use in organ transplantation
JP6909203B2 (ja)	2015-08-03	2021-07-28	バイオベラティブセラピューティクスインコーポレイテッド	第ｉｘ因子融合タンパク質及びそれらの製造方法及び使用方法
SI4209499T1 (sl)	2015-08-13	2025-01-31	Amgen Inc.	Globinsko nabito filtriranje proteinov, ki vežejo antigen
TW201707725A (zh)	2015-08-18	2017-03-01	美國馬友醫藥教育研究基金會	載體－抗體組合物及其製造及使用方法
IL307276B1 (en)	2015-08-28	2025-04-01	Amunix Operating Inc	Chimeric polypeptide composition and methods for its preparation and use
US11352426B2 (en)	2015-09-21	2022-06-07	Aptevo Research And Development Llc	CD3 binding polypeptides
AR106189A1 (es)	2015-10-02	2017-12-20	Hoffmann La Roche	ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO
WO2017055542A1 (en)	2015-10-02	2017-04-06	F. Hoffmann-La Roche Ag	Bispecific anti-human cd20/human transferrin receptor antibodies and methods of use
TW201713360A (en)	2015-10-06	2017-04-16	Mayo Foundation	Methods of treating cancer using compositions of antibodies and carrier proteins
AU2016350613B2 (en)	2015-11-02	2023-10-05	Bioatla, Llc	Conditionally active polypeptides
CN108699136B (zh)	2015-12-07	2022-03-18	Xencor股份有限公司	结合cd3和psma的异二聚抗体
IL299759A (en)	2015-12-30	2023-03-01	Genentech Inc	Formulations with reduced polysorbate dissolution
US11571469B2 (en)	2016-01-07	2023-02-07	Mayo Foundation For Medical Education And Research	Methods of treating cancer with interferon wherein the cancer cells are HLA negative or have reduced HLA expression
BR112018015659A2 (pt)	2016-02-01	2018-12-26	Bioverativ Therapeutics Inc	genes otimizados do fator viii
CA3014531A1 (en)	2016-02-12	2017-08-17	Mayo Foundation For Medical Education And Research	Hematologic cancer treatments
CN108699156A (zh)	2016-03-01	2018-10-23	豪夫迈·罗氏有限公司	具有降低的adcp的奥滨尤妥珠单抗和利妥昔单抗变体
WO2017149018A1 (en)	2016-03-02	2017-09-08	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods and kits for predicting the risk of relapse in patients suffering from idiopathic nephrotic syndrome
AU2017231749A1 (en)	2016-03-08	2018-09-20	Academia Sinica	Methods for modular synthesis of N-glycans and arrays thereof
MY195541A (en)	2016-03-14	2023-01-31	Univ Oslo	Engineered Immunoglobulins With Altered Fcrn Binding
EP3430058A4 (en)	2016-03-15	2019-10-23	Generon (Shanghai) Corporation Ltd.	MULTISPECIFIC FAB FUSION PROTEINS AND USES THEREOF
EP3432926A4 (en)	2016-03-21	2019-11-20	Mayo Foundation for Medical Education and Research	METHOD FOR REDUCING THE TOXICITY OF CHEMOTHERAPEUTICS
US11878061B2 (en)	2016-03-21	2024-01-23	Mayo Foundation For Medical Education And Research	Methods for improving the therapeutic index for a chemotherapeutic drug
CA3019373A1 (en)	2016-03-29	2017-10-05	Geltor, Inc.	Expression of proteins in gram-negative bacteria wherein the ratio of periplasmic volume to cytoplasmic volume is between 0.5:1 and 10:1
US10618969B2 (en)	2016-04-06	2020-04-14	Mayo Foundation For Medical Education And Research	Carrier-binding agent compositions and methods of making and using the same
MX394519B (es)	2016-04-15	2025-03-24	Macrogenics Inc	Moleculas de union b7-h3 novedosas, conjugados anticuerpo-farmaco de los mismos y metodos de uso de los mismos.
JP2019514870A (ja)	2016-04-22	2019-06-06	アンスティチュナショナルドゥラサンテエドゥラルシェルシュメディカル	Ｂ細胞悪性腫瘍の処置のための方法及びワクチン組成物
EA201892284A1 (ru)	2016-05-27	2019-08-30	Тг Терапьютикс, Инк.	Комбинация антитела против cd20, селективного ингибитора pi3-киназы-дельта и ингибитора btk для лечения b-клеточных пролиферативных расстройств
JP7010854B2 (ja)	2016-06-14	2022-01-26	ゼンコアインコーポレイテッド	二重特異性チェックポイント阻害剤抗体
EP3472197A1 (en)	2016-06-15	2019-04-24	Sutro Biopharma, Inc.	Antibodies with engineered ch2 domains, compositions thereof and methods of using the same
CA3029328A1 (en)	2016-06-28	2018-01-04	Xencor, Inc.	Heterodimeric antibodies that bind somatostatin receptor 2
WO2018013714A1 (en)	2016-07-13	2018-01-18	Biogen Ma Inc.	Dosage regimens of lingo-1 antagonists and uses for treatment of demyelinating disorders
JP2018035137A (ja)	2016-07-13	2018-03-08	マブイミューンダイアグノスティックスエイジーＭａｂｉｍｍｕｎｅＤｉａｇｎｏｓｔｉｃｓＡｇ	新規な抗線維芽細胞活性化タンパク質（ｆａｐ）結合薬剤およびその使用
GB201613167D0 (en)	2016-07-29	2016-09-14	Univ Southampton	Cancer and b-cell related disease therapy
CN109963868B (zh)	2016-08-22	2023-11-14	醣基生医股份有限公司	抗体、结合片段及使用方法
US10793632B2 (en)	2016-08-30	2020-10-06	Xencor, Inc.	Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
CN107384932B (zh)	2016-08-31	2020-10-20	北京天广实生物技术股份有限公司	抗人cd20人源化单克隆抗体mil62、其制备方法及用途
RU2019109211A (ru)	2016-09-01	2020-10-01	Мэйо Фаундейшн Фор Медикал Эдьюкейшн Энд Рисерч	Композиции, содержащие носитель-pd-l1-связывающий агент для лечения рака
JP2019526579A (ja)	2016-09-01	2019-09-19	マヨファウンデーションフォーメディカルエデュケーションアンドリサーチＭａｙｏＦｏｕｎｄａｔｉｏｎＦｏｒＭｅｄｉｃａｌＥｄｕｃａｔｉｏｎＡｎｄＲｅｓｅａｒｃｈ	Ｔ細胞癌を標的とする為の方法及び組成物
US11590098B2 (en)	2016-09-06	2023-02-28	Mayo Foundation For Medical Education And Research	Methods of treating triple-negative breast cancer using compositions of antibodies and carrier proteins
WO2018048958A1 (en)	2016-09-06	2018-03-15	Mayo Foundation For Medical Education And Research	Paclitaxel-albumin-binding agent compositions and methods for using and making the same
CN109843924A (zh)	2016-09-06	2019-06-04	梅约医学教育与研究基金会	治疗表达pd-l1的癌症的方法
CA3035976A1 (en)	2016-09-09	2018-03-15	Tg Therapeutics, Inc.	Combination of an anti-cd20 antibody, pi3 kinase-delta inhibitor, and anti-pd-1 or anti-pd-l1 antibody for treating hematological cancers
CN108421048B (zh) *	2016-09-28	2021-04-20	首都医科大学附属北京世纪坛医院	纳米活性碳靶向药物递送系统、制备方法及其用途
CN109862919A (zh)	2016-10-11	2019-06-07	免疫医疗有限公司	抗体-药物缀合物联合免疫介导的治疗剂
CA3039930A1 (en)	2016-10-14	2018-04-19	Xencor, Inc.	Bispecific heterodimeric fusion proteins containing il-15/il-15ralpha fc-fusion proteins and pd-1 antibody fragments
JP7341061B2 (ja)	2016-11-22	2023-09-08	エレクトロファイ，インコーポレイテッド	治療用又は診断用薬剤を含む粒子並びにその懸濁液及び使用方法
CA3045306A1 (en)	2016-11-29	2018-06-07	Boston Biomedical, Inc.	Naphthofuran derivatives, preparation, and methods of use thereof
US20200003785A1 (en)	2016-12-01	2020-01-02	Inserm (Institut National De La Sante Et De La Recherche Medicale)	Use of anti-uchl1 igg plasma concentration for diagnosing idiopathic steroid sensitive nephrotic syndrome
KR20190091292A (ko)	2016-12-02	2019-08-05	바이오버라티브 테라퓨틱스 인크.	응고 인자에 대한 면역 내성 유도 방법
MA46967A (fr)	2016-12-02	2019-10-09	Bioverativ Therapeutics Inc	Méthodes de traitement de l'arthropathie hémophilique à l'aide de facteurs de coagulation chimériques
CR20190389A (es)	2017-01-31	2019-11-26	Bioverativ Therapeutics Inc	Proteínas de fusión del factor ix y procedimientos de preparación y utilización de las mismas
GB201703876D0 (en)	2017-03-10	2017-04-26	Berlin-Chemie Ag	Pharmaceutical combinations
US10799597B2 (en)	2017-04-03	2020-10-13	Immunomedics, Inc.	Subcutaneous administration of antibody-drug conjugates for cancer therapy
EP3624846B1 (en)	2017-05-16	2024-08-07	Bhami's Research Laboratory, Pvt. Ltd.	High concentration protein formulations with reduced viscosity including a combination of nicotinic acid and tryoptophan
JP2020520923A (ja)	2017-05-17	2020-07-16	ボストンバイオメディカル，インコーポレイテッド	がんを処置するための方法
MA49517A (fr)	2017-06-30	2020-05-06	Xencor Inc	Protéines de fusion fc hétérodimères ciblées contenant il-15/il-15ra et domaines de liaison à l'antigène
EA202090020A1 (ru)	2017-07-10	2020-04-28	Интернэшнл - Драг - Дивелопмент - Байотек	Лечение b-клеточных злокачественных новообразований с использованием афукозилированных проапоптотических анти-cd19 антител в сочетании с анти-cd20 антителами или химиотерапевтическими средствами
AU2018306303A1 (en)	2017-07-25	2020-02-20	Elektrofi, Inc.	Formation of particles including agents
WO2019020606A1 (en)	2017-07-26	2019-01-31	F. Hoffmann-La Roche Ag	POLYTHERAPY WITH BET INHIBITOR, BCL-2 INHIBITOR AND ANTI-CD20 ANTIBODY
AU2018313921B2 (en)	2017-08-09	2024-12-19	Bioverativ Therapeutics Inc.	Nucleic acid molecules and uses thereof
US10759865B2 (en)	2017-08-22	2020-09-01	Eyal Levit	Treatment of diabetes mellitus
US11180541B2 (en)	2017-09-28	2021-11-23	Geltor, Inc.	Recombinant collagen and elastin molecules and uses thereof
WO2019077123A1 (en)	2017-10-20	2019-04-25	INSERM (Institut National de la Santé et de la Recherche Médicale)	METHODS AND KITS FOR IDENTIFYING WHETHER A SUBJECT IS REACHED OR RISK OF BEING WITH AUTOIMMUNE MYOPATHY
US10981992B2 (en)	2017-11-08	2021-04-20	Xencor, Inc.	Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
CN112272563A (zh)	2017-11-08	2021-01-26	Xencor股份有限公司	使用新颖抗pd-1序列的双特异性和单特异性抗体
WO2019118793A2 (en)	2017-12-14	2019-06-20	Ezy Biotech Llc	Subject-specific tumor inhibiting cells and the use thereof
EP3728302A1 (en)	2017-12-19	2020-10-28	Xencor, Inc.	Engineered il-2 fc fusion proteins
AU2019236372B2 (en)	2018-03-13	2024-06-20	F. Hoffmann-La Roche Ag	Therapeutic combination of 4-1 BB agonists with anti-CD20 antibodies
CA3094112A1 (en)	2018-03-28	2019-10-03	Bristol-Myers Squibb Company	Interleukin-2/interleukin-2 receptor alpha fusion proteins and methods of use
WO2019195623A2 (en)	2018-04-04	2019-10-10	Xencor, Inc.	Heterodimeric antibodies that bind fibroblast activation protein
CA3098128A1 (en)	2018-04-18	2019-10-24	Ucl Business Ltd	Engineered regulatory t cell
CN112867734A (zh)	2018-04-18	2021-05-28	Xencor股份有限公司	包含IL-15/IL-15Ra Fc融合蛋白和PD-1抗原结合结构域的靶向PD-1的异源二聚体融合蛋白及其用途
CA3097741A1 (en)	2018-04-18	2019-10-24	Xencor, Inc.	Tim-3 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and tim-3 antigen binding domains
AU2019261450B2 (en)	2018-04-27	2024-09-19	Biogen Ma Inc.	Human-derived anti-(poly-GA) dipeptide repeat (DPR) antibody
JP2021524449A (ja)	2018-05-23	2021-09-13	アーデーセーセラピューティクスソシエテアノニム	分子アジュバント
WO2019226969A1 (en)	2018-05-24	2019-11-28	Elektrofi, Inc.	Particles comprising a therapeutic or diagnostic agent and suspensions and methods of use thereof
AU2019299358A1 (en)	2018-07-03	2021-02-18	Bristol-Myers Squibb Company	Methods of producing recombinant proteins
EP3820475A4 (en)	2018-07-09	2022-04-13	Takeda Pharmaceutical Company Limited	Administration of sumo-activating enzyme inhibitor and anti-cd20 antibodies
WO2020028909A1 (en)	2018-08-03	2020-02-06	Brown University	Oral formulations with increased uptake
CN109273050B (zh) *	2018-08-03	2021-07-13	五邑大学	一种用于解析复杂多聚体蛋白受体的脉冲电子顺磁共振数据的系统及方法与应用
AU2019331024A1 (en)	2018-08-31	2021-03-18	Regeneron Pharmaceuticals, Inc.	Dosing strategy that mitigates cytokine release syndrome for CD3/C20 bispecific antibodies
US20210363245A1 (en)	2018-09-17	2021-11-25	The United States Of America,As Represented By The Secretary,Department Of Health And Human Services	Bicistronic chimeric antigen receptors targeting cd19 and cd20 and their uses
WO2020072821A2 (en)	2018-10-03	2020-04-09	Xencor, Inc.	Il-12 heterodimeric fc-fusion proteins
GB201816553D0 (en)	2018-10-10	2018-11-28	Centauri Therapeutics Ltd	Novel compounds and therapeutic uses thereof
GB201816554D0 (en)	2018-10-10	2018-11-28	Centauri Therapeutics Ltd	Novel compounds and therapeutic uses thereof
WO2020076776A1 (en)	2018-10-10	2020-04-16	Boehringer Ingelheim International Gmbh	Method for membrane gas transfer in high density bioreactor culture
CN113329769A (zh)	2018-10-11	2021-08-31	斯克里普斯研究学院	具有反应性精氨酸的抗体化合物及相关的抗体药物缀合物
KR102262012B1 (ko)	2018-10-15	2021-06-09	연세대학교 산학협력단	생산성이 향상된 항체 및 이의 제조방법
RU2724469C2 (ru)	2018-10-31	2020-06-23	Закрытое Акционерное Общество "Биокад"	Моноклональное антитело, которое специфически связывается с cd20
EP3875595A4 (en)	2018-11-02	2022-07-13	Kyowa Kirin Co., Ltd.	Liquid medium preparation method
US20220016277A1 (en)	2018-11-20	2022-01-20	Cornell University	Macrocyclic complexes of radionuclides and their use in radiotherapy of cancer
KR20210100668A (ko)	2018-12-06	2021-08-17	제넨테크, 인크.	항-CD79b 면역접합체, 알킬화제 및 항-CD20 항체를 포함하는 미만성 큰 B-세포 림프종의 조합 요법
US20220018835A1 (en)	2018-12-07	2022-01-20	INSERM (Institut National de la Santé et de la Recherche Médicale	Use of cd26 and cd39 as new phenotypic markers for assessing maturation of foxp3+ t cells and uses thereof for diagnostic purposes
JP2022523510A (ja)	2019-01-31	2022-04-25	エレクトロフィ，インコーポレイテッド	粒子形成及び形態構造
WO2020167912A1 (en)	2019-02-13	2020-08-20	The Brigham And Women's Hospital, Inc.	Anti-peripheral lymph node addressin antibodies and uses thereof
EP3927831A1 (en)	2019-02-18	2021-12-29	ATB Therapeutics	Method of producing a binder-toxin fusion protein in a plant cell or a whole plant
MX2021010313A (es)	2019-02-27	2021-09-23	Genentech Inc	Dosificacion para el tratamiento con anticuerpos anti-tigit y anti-cd20 o anti-cd38.
US11472890B2 (en)	2019-03-01	2022-10-18	Xencor, Inc.	Heterodimeric antibodies that bind ENPP3 and CD3
AU2020254582A1 (en)	2019-04-01	2021-09-30	Genentech, Inc.	Compositions and methods for stabilizing protein-containing formulations
SG11202111349QA (en)	2019-04-12	2021-11-29	Geltor Inc	Recombinant elastin and production thereof
TW202108178A (zh)	2019-05-14	2021-03-01	美商建南德克公司	使用抗CD79b免疫結合物治療濾泡性淋巴瘤之方法
EP3980423A1 (en)	2019-06-10	2022-04-13	Sutro Biopharma, Inc.	5h-pyrrolo[3,2-d]pyrimidine-2,4-diamino compounds and antibody conjugates thereof
EP3983410A1 (en)	2019-06-17	2022-04-20	Sutro Biopharma, Inc.	1-(4-(aminomethyl)benzyl)-2-butyl-2h-pyrazolo[3,4-c]quinolin-4-amine derivatives and related compounds as toll-like receptor (tlr) 7/8 agonists, as well as antibody drug conjugates thereof for use in cancer therapy and diagnosis
KR20220039777A (ko)	2019-08-01	2022-03-29	브리스톨-마이어스 스큅 컴퍼니	유가식 세포 배양에서 단백질 생산성을 개선시키는 방법
CA3149049A1 (en)	2019-08-30	2021-03-04	Vestlandets Innovasjonsselskap As	Method for the treatment of chronic fatigue syndrome using an inhibitory or cytotoxic agent against plasma cells
CN114340675A (zh)	2019-09-12	2022-04-12	豪夫迈·罗氏有限公司	治疗狼疮性肾炎的组合物和方法
WO2021050953A1 (en)	2019-09-13	2021-03-18	Elektrofi, Inc.	Compositions and methods for the delivery of therapeutic biologics for treatment of disease
WO2021076196A1 (en)	2019-10-18	2021-04-22	Genentech, Inc.	Methods of using anti-cd79b immunoconjugates to treat diffuse large b-cell lymphoma
WO2021100034A1 (en)	2019-11-19	2021-05-27	Protalix Ltd.	Removal of constructs from transformed cells
EP4096713A1 (en)	2020-01-31	2022-12-07	Seagen Inc.	Anti-cd30 antibody-drug conjugates and their use for the treatment of non-hodgkin lymphoma
US20230065628A1 (en)	2020-02-19	2023-03-02	Elektrofi, Inc.	Droplet Formation and Particle Morphology
WO2021178597A1 (en)	2020-03-03	2021-09-10	Sutro Biopharma, Inc.	Antibodies comprising site-specific glutamine tags, methods of their preparation and methods of their use
JP2023522627A (ja)	2020-04-17	2023-05-31	エレクトロフィ，インコーポレイテッド	連続的な液滴形成及び脱水によって粒子を形成する方法
TW202206111A (zh)	2020-04-24	2022-02-16	美商建南德克公司	使用抗ｃｄ７９ｂ免疫結合物之方法
WO2021218862A1 (en)	2020-04-26	2021-11-04	Biocytogen Pharmaceuticals (Beijing) Co., Ltd	Modified immunoglobulins
WO2021223048A1 (zh)	2020-05-03	2021-11-11	上海美雅珂生物技术有限责任公司	抗体药物偶联物及其制剂
US11919956B2 (en)	2020-05-14	2024-03-05	Xencor, Inc.	Heterodimeric antibodies that bind prostate specific membrane antigen (PSMA) and CD3
GB202007842D0 (en)	2020-05-26	2020-07-08	Quell Therapeutics Ltd	Polypeptide useful in adoptive cell therapy
WO2021262963A1 (en)	2020-06-24	2021-12-30	Bioverativ Therapeutics Inc.	Methods for the removal of free factor viii from preparations of lentiviral vectors modified to express said protein
JP2023536602A (ja)	2020-08-03	2023-08-28	ジェネンテック，インコーポレイテッド	リンパ腫のための診断及び治療方法
GB202012331D0 (en)	2020-08-07	2020-09-23	Petmedix Ltd	Therapeutic antibodies
IL300666A (en)	2020-08-19	2023-04-01	Xencor Inc	ANTI–CD28 COMPOSITIONS
CN112062855B (zh)	2020-08-26	2024-08-30	北京天诺健成医药科技有限公司	一种含有衔接器的药物治疗剂的开发和应用
WO2022043415A1 (en)	2020-08-27	2022-03-03	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods for detecting the presence of pemphigus-specific autoantibodies in a sample
GB202013477D0 (en)	2020-08-27	2020-10-14	Quell Therapeutics Ltd	Nucleic acid constructs for expressing polypeptides in cells
AU2021339006A1 (en)	2020-09-10	2023-04-13	Genmab A/S	Bispecific antibody against CD3 and CD20 in combination therapy for treating diffuse large B-cell lymphoma
KR20230066393A (ko)	2020-09-10	2023-05-15	젠맵 에이/에스	여포성 림프종을 치료하기 위한 조합 요법에서의 cd3 및 cd20에 대한 이중특이적 항체
CA3192251A1 (en)	2020-09-10	2022-03-17	Genmab A/S	Bispecific antibody against cd3 and cd20 in combination therapy for treating diffuse large b-cell lymphoma
MX2023002546A (es)	2020-09-10	2023-03-14	Genmab As	Anticuerpos biespecificos contra cumulo de diferenciacion 3 (cd3) y contra cumulo de diferenciacion 20 (cd20) para tratar leucemia linfocitica cronica.
AU2021341509A1 (en)	2020-09-10	2023-04-13	Genmab A/S	Bispecific antibody against CD3 and CD20 in combination therapy for treating follicular lymphoma
WO2022066595A1 (en)	2020-09-22	2022-03-31	Bristol-Myers Squibb Company	Methods for producing therapeutic proteins
EP4225902A1 (en)	2020-10-05	2023-08-16	Protalix Ltd.	Dicer-like knock-out plant cells
US20230372528A1 (en)	2020-10-16	2023-11-23	University Of Georgia Research Foundation, Inc.	Glycoconjugates
WO2022103983A2 (en)	2020-11-11	2022-05-19	Sutro Biopharma, Inc.	Fluorenylmethyloxycarbonyl and fluorenylmethylaminocarbonyl compounds, protein conjugates thereof, and methods for their use
WO2022104150A1 (en)	2020-11-12	2022-05-19	Tg Therapeutics, Inc.	Triple combination to treat b-cell malignancies
GB202102396D0 (en)	2021-02-19	2021-04-07	Adc Therapeutics Sa	Molecular adjuvant
EP4305067A1 (en)	2021-03-09	2024-01-17	Xencor, Inc.	Heterodimeric antibodies that bind cd3 and cldn6
WO2022192586A1 (en)	2021-03-10	2022-09-15	Xencor, Inc.	Heterodimeric antibodies that bind cd3 and gpc3
EP4308157A1 (en)	2021-03-15	2024-01-24	Genentech, Inc.	Compositions and methods of treating lupus nephritis
CA3212978A1 (en)	2021-03-24	2022-09-29	James N. KOCHENDERFER	Bicistronic chimeric antigen receptors designed to reduce retroviral recombination and uses thereof
JPWO2022224980A1 (xx)	2021-04-20	2022-10-27
EP4334354A1 (en)	2021-05-06	2024-03-13	Dana-Farber Cancer Institute, Inc.	Antibodies against alk and methods of use thereof
EP4337266A1 (en)	2021-05-12	2024-03-20	Genentech, Inc.	Methods of using anti-cd79b immunoconjugates to treat diffuse large b-cell lymphoma
EP4347647A1 (en)	2021-06-01	2024-04-10	Institut National de la Santé et de la Recherche Médicale (INSERM)	Use of b cell depleting agents for the treatment of rheumatic heart disease
KR20240018435A (ko)	2021-06-08	2024-02-13	사이포스 바이오사이언시스 인코포레이티드	항체-nkg2d 리간드 도메인 융합 단백질
AU2022291369A1 (en)	2021-06-08	2023-12-07	Xyphos Biosciences Inc.	Antibody-nkg2d ligand domain fusion protein
CA3224517A1 (en)	2021-06-17	2022-12-22	Petmedix Ltd	Anti canine cd20 antibodies
CA3220318A1 (en)	2021-06-17	2022-12-22	Glaxosmithkline Intellectual Property Limited	Anti-baff antibodies for use in a method of treatment of long covid and/or post-acute sequelae sars-cov-2 infection (pasc)
EP4377338A2 (en)	2021-07-27	2024-06-05	Novab, Inc.	Engineered vlrb antibodies with immune effector functions
US20250115666A1 (en)	2021-08-05	2025-04-10	Bristol-Myers Squibb Company	Cell culture methods for producing therapeutic proteins
AU2022321899A1 (en)	2021-08-06	2024-02-08	Petmedix Ltd	Antibody fc variants
US20240336697A1 (en)	2021-08-07	2024-10-10	Genentech, Inc.	Methods of using anti-cd79b immunoconjugates to treat diffuse large b-cell lymphoma
CA3229345A1 (en)	2021-08-23	2023-03-02	Bioverativ Therapeutics Inc.	Closed-end dna production with inverted terminal repeat sequences
AR126846A1 (es)	2021-08-23	2023-11-22	Bioverativ Therapeutics Inc	Genes del factor viii optimizados
WO2023049687A1 (en)	2021-09-21	2023-03-30	Bristol-Myers Squibb Company	Methods of controlling the level of dissolved oxygen (do) in a solution comprising a recombinant protein in a storage container
JP2024537797A (ja)	2021-09-30	2024-10-16	バイオベラティブセラピューティクスインコーポレイテッド	低下した免疫原性を有する第ｖｉｉｉ因子ポリペプチドをコードする核酸
TW202321308A (zh)	2021-09-30	2023-06-01	美商建南德克公司	使用抗ｔｉｇｉｔ抗體、抗ｃｄ３８抗體及ｐｄ—１軸結合拮抗劑治療血液癌症的方法
CN117980327A (zh)	2021-11-03	2024-05-03	杭州多禧生物科技有限公司	抗体的特异性偶联
CA3238936A1 (en)	2021-11-24	2023-06-01	Wayne A. Marasco	Antibodies against ctla-4 and methods of use thereof
EP4448575A2 (en)	2021-12-17	2024-10-23	Dana-Farber Cancer Institute, Inc.	Platform for antibody discovery
WO2023114544A1 (en)	2021-12-17	2023-06-22	Dana-Farber Cancer Institute, Inc.	Antibodies and uses thereof
MX2024008832A (es)	2022-01-28	2024-07-25	Genmab As	Anticuerpo biespecifico contra el cumulo de diferenciacion 3 (cd3) y el cumulo de diferenciacion 20 (cd20) en terapia combinada para tratar linfoma difuso de celulas b grandes.
WO2023150552A1 (en)	2022-02-04	2023-08-10	Dana-Farber Cancer Institute, Inc.	Compositions and methods for treatment of neurological disorders
AU2023219227A1 (en)	2022-02-09	2024-08-01	Petmedix Ltd	Therapeutic antibodies
WO2023164487A1 (en)	2022-02-22	2023-08-31	Brown University	Compositions and methods to achieve systemic uptake of particles following oral or mucosal administration
EP4508080A1 (en)	2022-04-11	2025-02-19	Astrazeneca AB	T cell binding proteins
KR20250029029A (ko)	2022-04-29	2025-03-04	일렉트로피, 아이엔씨.	주사가능한 현탁액
US11814439B1 (en)	2022-06-01	2023-11-14	Tg Therapeutics, Inc.	Anti-CD20 antibody compositions
US11965032B1 (en)	2022-06-01	2024-04-23	Tg Therapeutics, Inc.	Anti-CD20 antibody compositions
US11884740B1 (en)	2022-06-01	2024-01-30	Tg Therapeutics, Inc.	Anti-CD20 antibody compositions
US11807689B1 (en)	2022-06-01	2023-11-07	Tg Therapeutics, Inc.	Anti-CD20 antibody compositions
WO2024006272A1 (en)	2022-06-27	2024-01-04	Sutro Biopharma, Inc.	β-GLUCURONIDE LINKER-PAYLOADS, PROTEIN CONJUGATES THEREOF, AND METHODS THEREOF
WO2024015229A1 (en)	2022-07-15	2024-01-18	Sutro Biopharma, Inc.	Protease/enzyme cleavable linker-payloads and protein conjugates
WO2024039672A2 (en)	2022-08-15	2024-02-22	Dana-Farber Cancer Institute, Inc.	Antibodies against msln and methods of use thereof
WO2024039670A1 (en)	2022-08-15	2024-02-22	Dana-Farber Cancer Institute, Inc.	Antibodies against cldn4 and methods of use thereof
WO2024102734A1 (en)	2022-11-08	2024-05-16	Genentech, Inc.	Compositions and methods of treating childhood onset idiopathic nephrotic syndrome
WO2024153636A1 (en)	2023-01-17	2024-07-25	Institut National de la Santé et de la Recherche Médicale	Vasorin as a biomarker and biotarget in nephrology
TW202502363A (zh)	2023-02-28	2025-01-16	美商奇諾治療有限公司	用於治療全身性自體免疫疾病之細胞療法
WO2024254455A1 (en)	2023-06-08	2024-12-12	Genentech, Inc.	Macrophage signatures for diagnostic and therapeutic methods for lymphoma
WO2025021782A1 (en)	2023-07-24	2025-01-30	Institut National de la Santé et de la Recherche Médicale	Methods of determining whether a subject suffering from lupus nephritis (ln) will achieve a response with an induction therapy
US20250108048A1 (en)	2023-07-31	2025-04-03	Sutro Biopharma, Inc.	Sting agonist compounds and conjugates
WO2025045894A1 (en)	2023-08-28	2025-03-06	Institut National de la Santé et de la Recherche Médicale	Methods and kits for diagnosing cause of nephrotic syndrome and guiding therapy
WO2025054552A1 (en)	2023-09-08	2025-03-13	Elektrofi, Inc.	Particles and suspensions comprising hyaluronan degrading agents and methods of use thereof

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US26804A (en) *		1860-01-10		Bridle-bit
US206903A (en) *		1878-08-13		Improvement in cultivators
US21781A (en) *		1858-10-12		Improved method o f lighting street-lamps by electricity
US95963A (en) *		1869-10-19		Improvement in fence
US213784A (en) *		1879-04-01		Improvement in inlaying metallic scroll-ornaments in hard rubber and allied gums
US186205A (en) *		1877-01-16		Improvement in buffing-rolls for thesoles of boots andshoes
US147885A (en) *		1874-02-24		Improvement in the manufacture of halters and bridles
US163708A (en) *		1875-05-25		Improvement in harvester-rakes
US197255A (en) *		1877-11-20		Improvement in receivers and stench-traps for street-sewers
US9444A (en) *		1852-12-07		Hot-air furnace
US4816567A (en) *	1983-04-08	1989-03-28	Genentech, Inc.	Recombinant immunoglobin preparations
EP0173494A3 (en) *	1984-08-27	1987-11-25	The Board Of Trustees Of The Leland Stanford Junior University	Chimeric receptors by dna splicing and expression
USRE38008E1 (en) *	1986-10-09	2003-02-25	Neorx Corporation	Methods for improved targeting of antibody, antibody fragments, hormones and other targeting agents, and conjugates thereof
US6893625B1 (en) *	1986-10-27	2005-05-17	Royalty Pharma Finance Trust	Chimeric antibody with specificity to human B cell surface antigen
IL85035A0 (en) *	1987-01-08	1988-06-30	Int Genetic Eng	Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
US4975278A (en) *	1988-02-26	1990-12-04	Bristol-Myers Company	Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells
US5204244A (en) *	1987-10-27	1993-04-20	Oncogen	Production of chimeric antibodies by homologous recombination
US5439665A (en) *	1988-07-29	1995-08-08	Immunomedics	Detection and treatment of infectious and inflammatory lesions
IL162181A (en) *	1988-12-28	2006-04-10	Pdl Biopharma Inc	A method of producing humanized immunoglubulin, and polynucleotides encoding the same
CA2095141A1 (en) *	1990-11-05	1992-05-06	Ingegerd Hellstrom	Synergistic therapy with combinations of anti-tumor antibodies and biologically active agents
MX9204374A (es) *	1991-07-25	1993-03-01	Idec Pharma Corp	Anticuerpo recombinante y metodo para su produccion.
US5686072A (en) *	1992-06-17	1997-11-11	Board Of Regents, The University Of Texas	Epitope-specific monoclonal antibodies and immunotoxins and uses thereof
US5736137A (en) *	1992-11-13	1998-04-07	Idec Pharmaceuticals Corporation	Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
NZ258392A (en) *	1992-11-13	1997-09-22	Idec Pharma Corp	Chimeric and radiolabelled antibodies to the b lymphocyte cellsurface antigen bp35 (cd-20) and their use in the treatment of b cell lymphona
US5648267A (en) *	1992-11-13	1997-07-15	Idec Pharmaceuticals Corporation	Impaired dominant selectable marker sequence and intronic insertion strategies for enhancement of expression of gene product and expression vector systems comprising same
US5595721A (en) *	1993-09-16	1997-01-21	Coulter Pharmaceutical, Inc.	Radioimmunotherapy of lymphoma using anti-CD20
US5678180A (en) *	1995-06-07	1997-10-14	Hughes Electronics	Communication system and method providing dispatch and cellular interconnect communications
US6183744B1 (en) *	1997-03-24	2001-02-06	Immunomedics, Inc.	Immunotherapy of B-cell malignancies using anti-CD22 antibodies
US6306393B1 (en) *	1997-03-24	2001-10-23	Immunomedics, Inc.	Immunotherapy of B-cell malignancies using anti-CD22 antibodies

1993
- 1993-11-03 US US08/149,099 patent/US5736137A/en not_active Expired - Lifetime
- 1993-11-12 CN CN2004100488083A patent/CN1607006B/zh not_active Expired - Lifetime
- 1993-11-12 DK DK99123967T patent/DK1005870T3/da active
- 1993-11-12 CA CA002626445A patent/CA2626445A1/en not_active Withdrawn
- 1993-11-12 UA UA95062664A patent/UA27946C2/uk unknown
- 1993-11-12 PT PT08013898T patent/PT2000149E/pt unknown
- 1993-11-12 PL PL93320526A patent/PL175557B1/pl unknown
- 1993-11-12 AT AT99123967T patent/ATE421335T1/de active
- 1993-11-12 DE DE69334285T patent/DE69334285D1/de not_active Expired - Lifetime
- 1993-11-12 MY MYPI93002374A patent/MY111196A/en unknown
- 1993-11-12 CN CNB931214246A patent/CN1270774C/zh not_active Expired - Lifetime
- 1993-11-12 DE DE122009000070C patent/DE122009000070I1/de active Pending
- 1993-11-12 EP EP08013898A patent/EP2000149B1/en not_active Expired - Lifetime
- 1993-11-12 CN CN200610090080XA patent/CN101007850B/zh not_active Expired - Lifetime
- 1993-11-12 ZA ZA938466A patent/ZA938466B/xx unknown
- 1993-11-12 HU HU9501410A patent/HU219264B/hu active Protection Beyond IP Right Term
- 1993-11-12 IL IL10759193A patent/IL107591A/xx not_active IP Right Cessation
- 1993-11-12 SG SG1996002951A patent/SG45294A1/en unknown
- 1993-11-12 CN CN2006100900848A patent/CN101007851B/zh not_active Expired - Lifetime
- 1993-11-12 CN CN2006100900829A patent/CN1912111B/zh not_active Expired - Lifetime
- 1993-11-12 AT AT08013898T patent/ATE431158T1/de active
- 1993-11-12 ES ES08013898T patent/ES2326144T3/es not_active Expired - Lifetime
- 1993-11-12 ES ES99123967T patent/ES2321567T3/es not_active Expired - Lifetime
- 1993-11-12 PT PT99123967T patent/PT1005870E/pt unknown
- 1993-11-12 DK DK08013898T patent/DK2000149T3/da active
- 1993-11-12 DE DE69334259T patent/DE69334259D1/de not_active Expired - Lifetime
- 1993-11-12 KR KR1019950701928A patent/KR100365632B1/ko not_active IP Right Cessation
- 1993-12-14 TW TW082110578A patent/TW376320B/zh not_active IP Right Cessation
1997
- 1997-05-13 BR BR1100622-6A patent/BR1100622A/pt active IP Right Grant
2002
- 2002-03-14 US US10/096,964 patent/US20030082172A1/en not_active Abandoned
2004
- 2004-07-15 FR FR04C0018C patent/FR04C0018I2/fr active Active
2006
- 2006-07-07 GE GEAP20069498A patent/GEP20074162B/en unknown
2008
- 2008-01-11 HK HK08100409.7A patent/HK1109633A1/xx not_active IP Right Cessation
- 2008-01-11 HK HK08100410.4A patent/HK1109634A1/xx not_active IP Right Cessation
2009
- 2009-05-13 HK HK09104369.6A patent/HK1125574A1/xx not_active IP Right Cessation
- 2009-11-10 NL NL300424C patent/NL300424I1/nl unknown
- 2009-11-11 LU LU91620C patent/LU91620I2/fr unknown
2010
- 2010-01-06 GE GEAP200911620A patent/GEPI20105119B/en unknown
- 2010-01-06 GE GEAP201011620A patent/GEP20105119B/en unknown

Also Published As

Publication number	Publication date
FR04C0018I1 (xx)	2008-09-26
US20030082172A1 (en)	2003-05-01
ZA938466B (en)	1994-06-20
US5736137A (en)	1998-04-07
IL107591A0 (en)	1994-02-27
PT1005870E (pt)	2009-04-28
HUT72914A (en)	1996-06-28
DE122009000070I1 (de)	2010-02-11
CN101007851A (zh)	2007-08-01
LU91620I2 (fr)	2010-01-11
CN1912111B (zh)	2010-05-26
CN101007850A (zh)	2007-08-01
TW376320B (en)	1999-12-11
CN1607006B (zh)	2012-09-19
CA2626445A1 (en)	1994-05-26
GEPI20105119B (en)	2010-11-25
UA27946C2 (uk)	2000-10-16
DE69334259D1 (de)	2009-03-12
MY111196A (en)	1999-09-30
PT2000149E (pt)	2009-07-14
CN1270774C (zh)	2006-08-23
HU219264B (en)	2001-03-28
KR100365632B1 (ko)	2003-08-02
ATE421335T1 (de)	2009-02-15
EP2000149B1 (en)	2009-05-13
HK1109633A1 (en)	2008-06-13
SG45294A1 (en)	1998-01-16
FR04C0018I2 (xx)	2009-11-20
HK1125574A1 (en)	2009-08-14
CN1607006A (zh)	2005-04-20
HK1109634A1 (en)	2008-06-13
ES2326144T3 (es)	2009-10-01
DK1005870T3 (da)	2009-05-18
ATE431158T1 (de)	2009-05-15
NL300424I1 (nl)	2010-01-04
CN1094965A (zh)	1994-11-16
GEP20105119B (en)	2010-11-25
HU9501410D0 (en)	1995-06-28
ES2321567T3 (es)	2009-06-08
BR1100622A (pt)	2000-04-18
GEP20074162B (en)	2007-07-10
PL175557B1 (pl)	1999-01-29
CN1912111A (zh)	2007-02-14
EP2000149A1 (en)	2008-12-10
IL107591A (en)	2000-02-17
DE69334285D1 (de)	2009-06-25
CN101007850B (zh)	2012-05-30
CN101007851B (zh)	2012-09-12

Publication	Publication Date	Title
ATE431158T1 (de)	2009-05-15	Chimärischer anti-cd20-antikörper
NO2006011I1 (no)	2006-10-02	Ibritumomab
ATE169219T1 (de)	1998-08-15	Behandlung von katarakt mit 15-keto- prostaglandinderivaten
ATE146964T1 (de)	1997-01-15	Behandlung von katarakt mit prostacyclinverbindungen